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Abstract 
A lack of contraception use and contraceptive method discontinuation are 
common causes of unintended pregnancy in the Eastern Cape. The most 
common reason for method discontinuation among childbearing women is 
the unacceptable side effects of their contraceptive choices. Both depression 
and sexual dysfunction are given as side effects of contraceptive use; 
however, there is little evidence to support these effects. This randomised, 
single-blind controlled trial conducted in East London, South Africa, 
investigated the effects of the initiation of a long-acting injectable 
contraceptive, Depot Medroxyprogesterone Acetate (DMP A), compared with 
the initiation of a copper Intrauterine Contraceptive Device (Cu-IUD) after 
childbirth on depression and sexual functioning. After counselling, 242 
consenting pregnant women were randomised to receive DMP A or a Cu IUD 
within 48 hours of childbirth, in a ratio of 1:1. Primary outcome measures 
were depression and sexual dysfunction evaluated by validated instruments. 
Questionnaires were administered at baseline, and telephonically at one 
month and three months after randomisation. The telephonic interviewer 
was blinded to the participants' group allocation. English and Xhosa versions 
of the Beck Depression Inventory and the Edinburgh Postnatal Depression 
Scale were used to assess depression. The Arizona Sexual Functioning Scale 
was used to assess sexual functioning. For these primary outcomes, median 
scores between the intervention groups were compared, as well as the 
number of events (dichotomous data) in each intervention group. The 
relative effects of these interventions were summarised by calculating risk 
ratios, with 95% confidence intervals. Statistical tests used included the 
Shapiro-Wilk test, T-test, and Wilcoxon test. There were not consistently 
statistically significant differences in the risk of depression or sexual dysfunction 
between the intervention groups in this study. However, there was a trend 
towards more depression in the DMPA group which was statistically significant 
for mean EPDS score at the one month and for the BDI score three month 
assessments compared with the IUD group. There was also a trend to more 
sexual dysfunction with DMPA, but the only statistically significant difference 
was that fewer women in the DMPA group resumed sexual intercourse within 
the first month of treatment than in the IUD group. The author's 
recommendations from the study are that, firstly, family planning providers 
should inform women during contraceptive counselling that there is no 
certainty that DMPA causes depression and/or sexual dysfunction; however, 
it may do so in the postpartum period. Secondly, contraceptive users can 
continue to use DMPA with confidence as a convenient and effective method 
of preventing unintended pregnancy. Thirdly, the trend towards postpartum 
depression and sexual dysfunction in the DMPA group of this study justifies 
further research with a larger sample size, to include women from various 
social settings, and for a longer period of follow-up. Lastly, the Cu-IUD is a 
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Adverse effects Unfavourable, unpleasant and potentially harmful 
effects. 
Amenorrhoea No evidence of monthly menstruation. 
Contraception Methods and ways of avoiding getting pregnant. 
Depression It is a common mental disorder characterized by 
depressed mood and sleep disturbances. 
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prevention. 
Ectopic pregnancy Type of pregnancy that occurs outside the womb, in 
either the fallopian tubes or the abdomen. 
Endometrial cancer Cancer of the lining of the uterus 
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contraceptives administering hormone preparations in the form of 
injections. 
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Sexual function The perceived quality of the person's sexual life and 
relationships. 
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~~~ 
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- --
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Chapter 1: Introduction 
1.1 Introduction 
This chapter gives an overview of the unintended pregnancy burden as the 
basis for this study. This is followed by purpose of the study; research 
question and study hypothesis explanation. Thereafter, the significance of the 
study and overview of the research design used to answer the study question 
and to test the hypothesis are described. 
1.2 Background 
There is an epidemic of unintended pregnancy globally, with profound 
consequences for women, their families, and their communities (Gipson, 
Koenig & Hindin, 2008a). In 2012, it was estimated that over 222 million 
women have an unmet need for modern contraception (Singh S and Darroch 
JE, 2012). This need is greatest where the risks of maternal mortality are 
highest (Singh S and Darroch JE, 2012). 
Two-thirds of pregnancies worldwide are unintended (WHO and Gutmacher 
Institute, 2007).Unintended pregnancies may have significant risks for 
women and their families (Cheng et a1., 2009; Gipson, Koenig & Hindin, 
2008a). Women with unintended pregnancies that are continued to term are 
more likely to receive inadequate or delayed prenatal care, and have poorer 
health outcomes such as low infant birth weight, infant mortality, and 
maternal mortality and morbidity(Cheng et aI., 2009; Gipson, Koenig & 
19 
Hindin,2008b; Hook, ]963; Kost, Landry & Darroch, ]998; Najman et aI., 
1991).The unmet need for modern contraception is a significant contributor 
to unintended pregnancy (Mqhayi et a1., 2004).Two-thirds of unintended 
pregnancies occur in women not using any method of contraception (WHO 
and Gutmacher Institute, 2007). Many women at risk of unintended 
pregnancy may be interested in using contraception, but are unable to do so 
due to barriers to accessing contraception services; or they may choose not to 
use contraceptives due to concerns about health consequences and side 
effects. 
Contraceptive failure or non-use of contraception due to lack of access or 
unacceptable side effects are common causes for unintended pregnancy, 
many of which end in Termination of pregnancy (TOP) (Bankole, Singh & 
Haas, 1998). Locally, in East London, (a city in one of nine South African 
provinces), two-thirds of babies born at Cecilia Makiwane Hospital were 
results of unplanned pregnancies (Mshweshwe, 2008). Furthermore, 
examination of records from two TOP clinics at local hospitals (Cecilia 
Makiwane and Frere Hospitals) reveals that more than 4,000 TOP's are 
performed annually (author's examination of hospital records). The records 
demonstrate a high burden of unintended pregnancy within the East London 
Municipality. 
Researchers worldwide have been discussing the issue of contraceptive use, 
non-use and its effects for many years (Bryant, 2009; Draper et al., 201 0; 
Frost, 2008; Gakidou & Vayena, 2007). In 2005 at the World Summit of the 
20 
United Nations, most Governments committed to "achieve universal access 
to reproductive health by 2015" for their populations (Assembly, 2005). 
Again in 2010 at the United Nations General Assembly meeting on the 
Millennium Development Goals, Governments committed to "ensuring that 
all women, men and young people have information about, access to, and 
choice of wide possible range of safe, effective and acceptable methods of 
family planning" (United Nations, 2012). 
At the time of writing, the author has been employed at the Effective Care 
Research Unit of the East London Hospital Complex in the Eastern Cape of 
South Africa as a Midwife and Researcher for the past twelve years (12) 
years. In her experience as a midwife, she has come across pregnant women 
who are still dependant on their parents for financial support, or who are 
from very poor families ... Based on these daily observations, one is forced to 
ask the question, "How are the available family planning methods failing to 
meet women's sexual health needs? ". 
To understand why some women continue to choose TOP rather than 
consistently a reliable method of contraception, the researcher has spoken to 
women accessing reproductive health care services. Several remarks from 
informal discussions with women of reproductive age indicated that their 
non-use of contraceptives was because of the side effects. To quote an 
example of such comment, one woman stated, "I am not going for the 
injection again. I cannot lose my boyfriend because he always complains that 
when I use the injectable contraceptive, he does not enjoy having sex with 
21 
me". Another woman, told the researcher "I do not like the altered mood 
effects of the Depo injection" medroxyprogesterone acetate (DMPA). 
Unacceptable side effects are the most common reason for discontin uation of 
contraception(Barden-O'Fallon et al., 2009; Gilliam et al., 2004; Paul, Skegg & 
Williams, 1997).While it had been found that hormonal contraception can 
alter menstruation(Abdel-Aleem et al., 2007; Berenson et al., 2008), limited 
data exists to support the possible interaction between hormonal 
contraception and mood or sexual functioning(Folger et al., 2013;World 
Health Organisation, 2009). 
During the development of medical eligibility criteria for contraceptive use, 
the World Health Organisation and the Centres for Disease Control 
identified a research gap about the association between hormonal 
contraception and depressive disorders (WorldHealth 
Organisation,2009).The question identified was, "Does the use of hormonal 
contraceptives exacerbate depressive disorders, including postpartum 
depression?" (Folger et al., 2010). 
Hence revised contraceptive guidelines produced by the South African 
Government Department of Health (2012) do refer to mood swings as a 
possible side effect of Depo-Provera. The South African Minister of Health, 
Dr Aaron Motswaledi, made a call in his preamble of the contraceptive 
guidelines to health workers to prioritise evidence-guided care, by ensuring 
that policy is informed by local research (Department of Health, 2012). 
22 
Unintended pregnancy is a problem in the East London setting; fear of side 
effects, or side effects actually experienced by users, are likely contributors to 
unintended pregnancy and the high prevalence of abortion in East London. 
The question of whether DMPA leads to depression or sexual dysfunction, 
remain unanswered and of public health importance. 
1.1. Statement of the Proble11l 
Contraceptive non-use and method discontinuation are common causes of 
unintended pregnancy (Paul, Skegg & Williams, 1997). Several studies have 
reported that unacceptable side effects area common reason for contraceptive 
method discontinuation (Barden-O'Fallon et aL, 2009; Brunner Huber et aL, 
2006; Gilliam et al., 2004; Paul, Skegg & Williams, 1997). 
Berga and Smith (2012) theorise that depot medroxyprogesterone acetate 
(DMPA) suppresses endogenous ovarian function as well as producing 
progestin dominant hormonal exposure. These changes can potentially affect 
both libido and the functioning of the reproductive tract. The authors 
hypothesize that decreased oestrogen results in less vaginal lubrication, 
thereby leading to sexual dysfunction (Berga & Smith, 2012). 
This study compares the relative effects of two long acting contraceptive 
methods (DMPA versus the non-hormonal copper intrauterine device 
(Copper T380a [Cu-IUD]), on depression and sexual dysfunction in women 
postpartum for a duration of three months. Both depression and sexual 
dysfunction are given as potential side effects of hormonal contraceptive use 
(Westhoff et aL, 1998); however, limited evidence exists to support this claim. 
23 
The Cu-IUD is a non-hormonal method, with no proven or theoretical risk of 
depression or sexual dysfunction (Gabalci & Terzioglu, 2010); therefore, the 
Cu-IUD method provides a good 'control' comparison with the hormonal 
intervention (DMPA) evaluated in this study. In a double blind placebo 
controlled study, injectable Progestogen contraception (Norethisterone 
Enanthate) in the postpartum period was associated with increased 
depression and reduced serum estradiol and progesterone levels (Lawrie et 
al, 1998).The majority of women in South Africa who use a modern 
contraceptive rely on DMPA(Depo-Provera®) for contraception (United 
Nations, Department of Economic and Social Affairs, Population Division, 
2012}.Women react differently to different contraceptive methods, and the 
use of family planning services is directly linked to the variety of 
contraceptive options offered to women(Hofmeyr, Singata & Lawrie, 
2010).As reported by previous researchers studies, 1/ choice of contraceptive 
methods depends on many factors such as effectiveness, potential adverse 
effects or convenience as well as the couple'S medical condition, sociocultural 
profile or reproductive intentions and beliefs" (Lopez-del Burgo et al., 2012; 
Oddens, 1997). 
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1.2. Purpose of the Study 
The purpose of this randomized controlled trial (RCT) is to determine 
whether the use of DMPA for contraception, compared to the Cu-IUD, is 
associated with and increased risk of depression and reduced sexual 
functioning amongst women of reproductive age in the Eastern Cape, South 
Africa. 
1.3. Justifications for the study 
An RCT, conducted in South Africa in Gauteng Province, found that the 
injectable Norethisterone contraceptive (NET-EN), was associated with an 
increased risk of postpartum depression at six weeks after delivery, when 
given to women after the birth of their baby (Lawrie et a1., 1998b). However, 
to the researcher's knowledge, no clinical trials have compared the relative 
effects of DMPA and NET-EN on postpartum depression; neither has the 
postpartum effects of these drugs on mood and sexual functioning been 
compared with the non-hormonal IUD 
It was important to the researcher to conduct this study in the Eastern Cape 
Province because the rate of unintended and unwanted pregnancies in the 
province requires urgent attention (Mshweshwe, 2008). The counselling 
during the initiation of any contraceptive method includes discussion of 
possible side effects of the method (WHO, 2012) . Therefore, information 
obtained about the two possible side effects under investigation in this study 
would be helpful to inform contraceptive users of both DMPA and IUD. 
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There is evidence and strong advocacy from various studies that the 
acceptability of a contraceptive method is increased when users are well 
informed about its side effects (Blumenthal, Voedisch & Gemzell-Danielsson, 
2011; Hubacher et a1., 1999; Hubacher et a1., 2(09).In addition, reliable data 
on the occurrence of known side effects with any contraceptive method is 
essential for clinicians in managing patients properly(Barden-O'FaIIon et a1., 
2(09). 
In light of the detected research gap the present study addresses the 
following questions: 
1.4. Research Questions 
• Is there any effect of injectable Progestogen on the risk of 
depression as compared to the Cu-IUD (Copper T 380A)? 
• Is there any effect of injectable Progestogen on sexual functioning 
as compared to the Cu-IUD? 
1.4.1. Hypotheses 
Null hypothesis 
• There is no statistically significant difference in the incidence of 
depression between women of reproductive age residing in the 
Eastern Cape allocated to use the Cu-IUD and those allocated to use 
injectable DMP A. 
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• There is no statistically significant difference in sexual functioning of 
women of reproductive age residing in the Eastern Cape allocated to 
use the Cu-IUD and those allocated to injectable DMPA. 
Alternative hypothesis 
• The use of injectable DMPA given to women of reproductive age, who 
wish to practice birth control, will result in a statistically significant 
difference in the incidence of depression compared to women who 
received the Cu-IUD. 
• The use of injectable DMPA given to women of reproductive age, who 
want to practice birth control, will result in a statistically significant 
difference in the level of sexual functioning compared to women who 
received the Cu-IUD. 
1.5. Significance of the Study 
Firstly, to the researcher's knowledge this study is unique to Southern Africa 
with special reference to South Africa. It will provide new evidence to 
determine whether the injectable DMPA as compared to the Cu IUD has 
causal effects on depressive symptoms and sexual dysfunction. 
Secondly, it will contribute to address unmet needs of women who request 
DMPA by adding information about possible side effects, such as depression 
and sexual functioning. The knowledge would enable family planning 
providers to counsel women requesting contraception. 
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Thirdly, it will assist policy-makers in drawing up informed guidelines and 
contraceptive policies. Such informed guidelines would ensure evidence-
based practice that would allow for a well thought-out, systematic approach 
in managing patients with specific needs. 
Fourthly, this study might be able to contribute to a systematic review that 
examines depression and/ or sexual functioning based on its study design (a 
ReT) and the quality of the evidence. 
1.6. Overview of the design appropriateness 
An ReT is the 'gold standard' for evaluating the effects of clinical 
interventions. The strength of an ReT, when conducted properly, is that it 
reduces the risk of serious imbalance of known and unknown factors 
(Stolberg, Norman & Trop, 2004). One example of these factors is trial 
treatment non adherence that could influence the clinical outcome (Stolberg, 
Norman & Trop, 2004). 
In this ReT, women were randomized to one of two groups: the injectable 
DMPA or the eu-IUD. This means that each woman had an equal chance of 
receiving either contraceptive method. By randomly allocating participating 
women to intervention groups, the risk of introducing selection bias into the 
study was minimized. One can, therefore, be more certain that any 
differences between the interventions are due to the intervention and not due 
to differences between the study groups. Randomisation should control 
various confounding factors, such as HIV infection, stillbirth and age 
(Katzenellenbogen, G Joubert & S S Abdool Karim, 1997). Without proper 
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control of confounders, bias can alter a study's findings and cause improper 
conclusions (Schulz & Grimes, 2002). 
The aim of a randomized controlled trial is to classify features, count them, 
and construct statistical models in an attempt to explain observations 
(Feldblum et a1., 2005). The researcher has used the Consort 20l0-statement 
guidance to report the results of the study to give more clarity, completeness, 
and transparent reporting (Schulz, Altman & Moher, 2010). 
1.7. Study Outcomes 
] .7.1. Primary Outcomes 
Measured at one month and three months postpartum: 
• Mean /median depression scores measured by the EPDS and the Beck 
Depression Inventory (BDI) (Aaron T. Beck, Robert A. Steer, Gregory 
K. Brown, 1996). 
• Depression (mild to severe) measured by the Edinburgh Postnatal 
Depression Scale (EPDS) (Cox, Holden & Sagovsky, 1987). 
• Depression (mild to severe) measured by the BDI (Aaron T. Beck, 
Robert A. Steer, Gregory K. Brown, 1996) at one month and three 
months postpartum. 
• Major depression measured by EPDS and BDI-II. 
• Sexual dysfunction as measured by the Arizona Sexual Experience 
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1.8. Preview of remailling Chapters of the Thesis 
1.8.1. Chapter 2 
This chapter describes literature that is relevant to family planning in 
general. The demographic profile of the Eastern Cape is explored; different 
contraceptive methods are discussed. Lastly, the literature on the two 
contraceptive methods evaluated in this study is explored. 
1.8.2. Chapter 3 
This chapter is divided into two sections. The first section explores literature 
on depression and, in particular, postpartum depression (PPD). Included is 
the prevalence of PPD in low and middle income countries, and risk factors 
of PPO, and the effects of PPD on both mother and baby are discussed. The 
second section explores literature on sexual functioning, different sexual 
response cycles, and sexual dysfunction during the postpartum period, and 
the potential effects of contraception on sexual functioning. 
1.8.3. Chapter 4 
The chapter presents the hierarchy of study design that led to the need to the 
selection of a randomised controlled trial methodology to conduct this study. 
It describes the study design, research sites, study population, sample size 
calculation, inclusion and exclusion criteria, recruitment and randomisation 
procedures and the instruments for data collection. It also describes the 
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results of the pilot study. In addition, this chapter includes the methods for 
determining validity and reliability of the instruments, data collection, 
ethical considerations, data management and analysis. Finally, the chapter 
explains the risks and benefits of taking part in the study, and the referral 
system put in place to support study participants. 
1.8.4. Chapter 5 
This chapter presents the flow of participants through the study, baseline 
characteristics of the sample and the results of primary and secondarv 
outcomes. 
1.8.5. Chapter 6 
This chapter aims to put into context, discussing associated literature that 
aids to clarify why the results observed might have been anticipated and 
how this influence our understanding of DMPA and IUD effect on 
Depression and Sexual functioning. 
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Chapter 2: Literature Review 
2.1 Introduction 
This chapter describes literature that is relevant to family planning in 
general. The demographic profile of the Eastern Cape is explored; different 
contraceptive methods are discussed. Lastly, the literature on the two 
contraceptive methods evaluated in this study is explored. 
The choice of birth control method selected by couples depends on several 
factors. These include factors, such as effectiveness, possible adverse effects 
and convenience, as well as the couple's medical conditions, sociocultural 
profile or reproductive intentions and beliefs (Lopez-del Burgo et aI, 2012). 
2.2 Source of search 
A literature search was conducted to gain contextual information and a more 
in-depth understanding of issues surrounding DMPA and Cu-IUD use 
internationally and in the Eastern Cape. International and national literature 
was reviewed to evaluate the existing evidence regarding the impact (if any) 
of DMPA and the Cu-IUD on depression and sexual function. 
The following databases were searched for RCT's comparing progestogen 
contraceptives with IUD's: MEDLINE, EMBASE, Science Direct, Scopus, 
Cinahl, Pop line, Coogle scholar and Pascal. 
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2.4 Pop"/atio,, I'rofil .. 
According to the mid-year population estiIl'Ultes 012013 bv It;., South African 
StatistiC" Office, the pupubhun of South Africa was f'stimated to bE' over 
fifty-two million (52,982,000) and out of this number over forty-two 
(42,284, 100) are Black Africans. The Eastern Cape population was estimated 
at over six million (6,620100.00). The Eastern Cape had the third highest 
population in the nine South African provinces (Statistics South Africa, 2011). 
The provincial average total fertility rate for the period 2011-2016 was 
projected as 2.70 for the Eastern Cape, higher than in all other provinces in 
the country (Stats SA, 2013) .. Cross-national quantitative data of seventy-nine 
(79) low development countries suggest that an economic dependency may 
have an indirect effect on maternal mortality (Shen & Williamson, 1999). 
2.5 Socio-economics of the Easte1'1l Cape 
Economic conditions are a determinant of most health outcomes(Brennan 
Ramirez, Baker & Metzler, 2008).A quarterly labour-force survey conducted 
by Statistics South Africa revealed that the Eastern Cape has an 
unemployment rate of 30.2% which has increased from 29.3 in the fourth 
quarter of 2012(Statistics South Africa, 2011).This is an improvement from 
the unemployment rate of 48.5% which was reported by Zere and McIntyre 
in their survey 20 years ago before democratic elections in South Africa(Zere 
& McIntyre, 2003). However, at the time of writing, there are still many 
women who depend on South African Child Support grants to take care of 
their families, living below the poverty line of less than R 250 a month, 
totalling about 8.2 million beneficiaries (Coovadia et aI., 2009; Goldblatt, 
2005). 
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Some association has been shown, in a survey conducted in five developed 
countries, (Canada, France, Great Britain, Sweden and USA), between 
poverty, unemployment and sexual behaviour as well as use of contraception 
(Singh, Darroch & Frost, 2001). Despite the high economic status of these 
countries, high birth rates and lower contraception use were reported in 
women with socioeconomic disadvantages, compared with the USA, where 
contraceptive use is high (Singh, Darroch & Frost, 2001). Similarly high birth 
rates among South African women are associated with socioeconomic 
disadvantage and minimal education standards (Chopra et al., 2009). 
Long-acting reversible contraceptives (LARC) have a low failure rate(Secura 
et a1., 2010) and, by effectively controlling population growth, have the 
potential to contribute to the eradication of extreme poverty and hunger, 
"Millennium Development Goal-l(MDG)//(United Nations, 2000; United 
Nations, 2012). 
2.5.1 Rites of passage for women in the Eastern Cape 
Transition from childhood varies in different cultural settings; however, 
biologically a girl converts from being a child to be a woman, ready to bear 
children, when she has her first menstrual period, as a sign that her body is 
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now producing eggs for reproduction (Rembeck, Moller & Gunnarsson, 
2006) 
Amongst the Xhosa's tribes of the Cape of South Africa, there used to be rites 
of passage (Intonjanc)for young girls to womanhood(Finlayson, 1998)and 
virginity testing is undertaken at the end of il1tonjanc (Tassiopoulos & 
Nuntsu, 2005).A difference between a Xhosa girl's initiation and that of girls 
from other African countries is that it does not involve genital 
circumcision(Finlayson, 1998; Khalil, 2006).Female genital circumcision is 
still widely practiced in some African countries although not as high as it 
used to be (Khalil, 2006). 
In other discipline like Anthropology, Silverman (2004) has explored the 
topic of female circumcision to understand the moral purpose of the 
practice(Silverman, 2004).Due to increasing migration to South Africa, 
midwifes need to be aware of female circumcision and its impact on 
maternity care(Berg 2010; Collinet 2004). 
2.5.2 Inequalities of role and function between men and women 
In some South African communities, there is still the expectation that women 
are to have children(Wood & Jewkes, 2006), should not go to school, and no 
investment should be made to educate them(Hari,1998).These studies 
support the idea that education is the key for the emancipation of women in 
South Africa. 
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This is further supported by the second Millennium Development Goal, 
which is to achieve universal primary education. MDG-2 cannot be achieved 
if women continue to have unintended pregnancies (Black, Devereux & 
Salvanes, 2005).In Norway, larger family size has been shown to have a 
negative effect on education (Black, Devereux & Salvanes, 2005), as does 
poor child spacing (Black, Devereux & Sal vanes, 2005),(Bates, Maselko & 
Schuler, 2007). Achieving MDG-2, will contribute towards achieving MDG-3, 
which is to "Promote gender equality and empower women" (United 
Nations, 2000). In order to empower women in South Africa and other 
developing countries, it is necessary to provide confidential reproductive 
health services to meet their needs, and in order to space pregnancies 
appropriately. 
2.6 Health services provision in the Eastern Cape 
2.6.1 Health services provision 
It is well-recognized that the reproductive health should be accessible, and 
facilities should provide privacy for women to meet all their reproductive 
needs (Indigo& Naidoo, 2010; Sheeder, Tocce & Stevens-Simon, 2009). In 
South Africa, the first point of entry into the health services starts in primary 
health care settings, which are local clinics that are supposed to be accessible 
within 10km reach of one's home (Dookie & Singh, 2012). 
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In 1996, a policy of an integrated health care approach was adapted by the 
South African government (Cooper et aI., 2004); whereby a reproductive 
health service should include antenatal services, delivery, postnatal care and 
family planning (Chopra et aI., 2009). 
2.7 Histories of family planning and birth control 
2.7.1 International perspectives 
In the early 20th century, use of birth control was disapproved of by the then 
President of the United States, Theodore Roosevelt. According to Bullough, 
Roosevelt saw birth control as a weapon to kill the white race (Bullough, 
2001). Similarly in South Africa during the apartheid period, emphasis was 
placed for more vigorous use of contraceptive by blacks than whites 
population, as black's fertility rate was much higher and this was viewed as 
a threat to whites population(Burgards & Lee-Rife, 2009). 
Margaret Sanger is cited by researchers as the person who established the 
American Birth Control League in 1921 to open birth control clinics(Chesler, 
2007; Sanger, 1920).5he managed to set-up the first legal birth control clinic 
in the US named the Birth Control Clinical Research Bureau(Sanger, 1920). 
Later on, the American Birth Control League changed its name to the 
Planned Parenthood Federation, which still exists today(Bullough, 2001). 
Reviewing contraceptive use in the USA, Piccinino and Mosher (1998) 
showed that there was an increase in the use of contraceptives from 56% in 
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1982 to 64 % in 1995. They also found that female sterilisation increased, from 
23.2% in 1983 to 38% 1995(Piccinino & Mosher, 1998). Injectable 
contraceptives were not used in the 1980's and only 3% used in 1995.Use of 
the male condom (Piccinino & Mosher, 1998) gradually increased between 
1982 and 1995 to 20.4%. Although there were other family planning methods 
used, IUD usage decrease over time from 7.1% 1982 to 0.8% in 1995 
(Piccinino & Mosher, 1998). 
History reveals that one of other factors that motivated high fertility was a 
perception that having a big family is a sign of wealth (Pollak & Watkins, 
1993).Findings of WHO and Gutmacher Institute (2007) have showed that in 
the twentieth century globally two- thirds of pregnancies are unintended as 
alluded to already in the first chapter. 
2.7.2 South Africa 
Birth control has been used since 1930 in South Africa(Kaufman et al., 
2004).At that time, it was available to the white population group only 
during the South African apartheid era in the 1970's, modern contraceptives 
were then promoted among black women (Brown, 1987) and this was 
perceived by blacks as a political programme to control the population 
growth of blacks (Brown, 1987; Burgard, 2004).Despite this, South Africa 
has managed to have a high contraceptive prevalence among all population 
groups compared to other sub-Saharan African countries(Cooper et al., 2004). 
The most used contraceptive methods in South Africa are injectable 
progestogen (mainly DMPA) and oral contraceptives (Mqhayi et al., 
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2004).The DOH is, at time of writing, reintroducing other LARC, including 
the Cu-IUD(Department of Health, 2012). Despite freely available 
contraceptives, unintended pregnancies are still a challenge (Mqhayi et aI., 
2004). 
2.8 Types of family planning and birth control methods 
2.8.1 Traditional methods 
In the Zulu tribe of KwaZulu Natal province, there is an annual ceremony to 
check the virginity of girls. This practice discourages girls from engaging in 
sexual activity until married (Scorgie, 2002).Keeping girls as virgins has an 
added benefit of birth control and helps in the reduction of new HIV 
transmission to young girls(Naidu, 2008). However, there are some concerns 
from researchers who have conducted studies on the practice of ukuhlolwa 
(virginity test) those girls not seen to be good enough to be brides may 
experience discrimination (Naidu, 2008). 
Similarly in Turkey, virginity testing is also conducted. However, the 
difference with the Zulu practice is that the test is conducted by medical 
doctors in their private practice, although it is not a legalised practice in 
Turkey. Some see it as a violation of a woman's freedom to control her own 
body (pahinoolu Pelin, 1999). 
Withdrawal (coitus interruptus) is one of the methods that couples can use to 
prevent pregnancy but efficacy depends" on the motivation and ability" to 
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practice the method correctly (WHO, 2012).Its mode of action is the 
prevention of sperm from entering the vagina. This method has no side effect 
however it is not protective of HIV and STIs. 
The other methods that falls under traditional methods are lactation 
amenorrhea method (LAM). The mode of action of LAM in preventing 
pregnancy is ovulation suppression. Reported to be highly effective if a 
women is fully breastfeeding and has amenorrhoea and less than 6 months 
postpartum (Trussell, 2011; Van der Wijden, Kleijnen & Van den Berk, 2003; 
WHO, 2012).Furthermore report from the Eastern Turkey study showed that 
there was non- adherence to the influential factors of LAM which influence 
effectiveness, about 82.8% of their participants could not adhere (Tiirk, 
Terzioglu,& Eroglu, 2010). 
LAM has been reported as having the added benefit of preventing mix 
feeding in a Jordan study (Bongiovanni et a1., 2013).Added to that it is 
reported as a method that has no side effects (Stone-Jimenez, Kouyate & 
Bongiovanni) . 
Fertility awareness-based (FAB) methods are reported to be 75% effective 
(WHO, 2012). However, women need to be able to identify their fertile 
window. FAB methods need commitment from both partners as they need to 
use a condom or abstain from sexual intercourse during the fertile phase 
period. Although all the traditional contraception need commitment and 
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discipline but some women use them to avoid side effects of modern family 
planning methods (Khalaf et aL, 2008). 
2.8.2 Intrauterine contraception 
2.8.2.1 Copper il7 trau terine device 
The Cu-IUD is a small device made of plastic and copper, that is placed in 
the uterus as a method of contraception (Hatcher et aL, 2008) . The main 
mechanism of action of the Cu-IUD is spermicidal (Hatcher et al, 2008). It is 
one of the most effective forms of contraception available, and is widely used 
globally (Hatcher et al., 2008; United Nations, 2011).Just like other 
contraceptive methods, the IUD has some advantages and disadvantages. 
Advl1ntl1ges and disl1dvl1ntl1ges of the Cu-JUD 
Advantages include no hormonal effects, no amenorrhoea, and immediate 
return to fertility on removal of the device (Hatcher et a!, 2008). Other 
advantages of the IUD are that a single insertion lasts up to 12 years, and 
could be left in place until after the menopause (Bhathena & Guillebaud, 
2006; Sivin, 2007). Additionally, the IUD reduces the risk of haemorrhagic 
stroke compared to combined hormonal methods,(Li et aL, 2006) and has a 
lower rate of discontinuation than other family planning methods (Singh, 
Roy & Singh, 2010; Winner et a1., 2012).In a systematic review Cu-IUD was 
found to have a lower rate of pregnancy compared to hormonal 
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contraception (Hofmeyr, Singata & Lawrie, 2010) .Also Cu-IUD is safe for use 
by HIV positive women (Curtis, Nanda & Kapp, 2009; Stringer et a1., 2009). 
According to El-Hefnawy et aI, (2008) the main disadvantages of IUDs are 
that the first insertion may be painful, and requires a skilled provider to 
insert. Other disadvantages include increased menstrual flow, painful 
menstruation, and rare complications include uterine perforation and 
expulsion of the device (El-Hefnawy et a1., 2008). 
Nevertheless, modern Cu-IUDs are safe, effective, and quickly reversible 
LARCs that require little attention after insertion (Salem, 2006). Declining 
use of the Cu-IUD in Ghana has been attributed to rumour about adverse 
effects, and worries about vaginal bleeding and weight loss (Osei et a1., 2005). 
Assessment of research findings, translated into guidance by the World 
Health Organization (WHO), should help encourage providers that most 
women can use Cu-IUDs (Salem, 2006; World Health Organization. 
Reproductive Health, 2010). 
According to Zhou & Xiao (2001), the main reasons for requesting removal of 
the Cu-IUD are heavy menstrual bleeding and pain (Zhou & Xiao, 2001). A 
randomized trial of prophylactic ibuprofen found no reduction in removal 
rates with this treatment(Hubacher et aI., 2006), while other randomised 
trials found that the increase in menstrual blood loss with the IUD was 
prevented with ibuprofen (Grimes et a1., 2006), tranexamic acid (Ylikorkala & 
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Viinikka, 1983) and to a lesser extent diclofenac sodium (Hubacher et al, 
2006). 
2.8.2.2 Levonorgestrcl releasing intrauterine system 
Levonorgerstrel intrauterine system(LNG-IUS),marketed under the brand 
name Mirena (WHO, 2012), is aT-shaped plastic device that steadily 
releases small amount of Levonorgestrel (progestin) each day (French et aI., 
2003).LNG-IUD prevents pregnancy by suppressing the growth of 
endometrium (WHO, 2012). It a highly effective contraceptive method, with 
an advantage of high continuation rate similar to the Cu-IUD (Shaamash et 
aI., 20(5), and can also be used to reduce heavy menstrual flow (Baldaszti, 
Wimmer-Puchinger & Loschke, 2003; French et al., 2(04).However, it is much 
expensive when compared to the Cu-IUD(Trussell et al., 2009). 
2.8.3 Hormonal contraception 
2.8.3.1 Combined hormonal contraceptive 
The combined oral contraceptive (COC), vaginal ring and patch all work in 
the same way by inhibiting follicular development, growth of the 
endometrial lining, and ovulation (Department of Health, 2012; Edelman et 
al., 2010). Oral contraceptives improve dysmenorrhea, acne and are reported 
to lower the risk of pelvic inflammatory disease (PID) (Mishell, 2010). 
However, COCs have some disadvantages as well. They have a high rate of 
method discontinuation (Westhoff et aI., 2007a; Winner et al., 2012) and 
45 
require daily intake for perfect use or it may result in unintended 
pregnancy(Blumenthal, Voedisch & Gemzell-Danielsson, 2011).Irregular 
bleeding is also another adverse event experienced by OC users (Barden-
O'Fallon et aL, 2009; Gilliam et aL, 2004; O'Connell, Davis & Kerns, 2007a; 
Sabatini & Cagiano, 2006; Westhoff et aL, 2007b). 
Progestogen only contraceptives 
Progestogen-onltl pills 
Progestogen-only pills (POP's) are estrogen-free oral contraceptives 
containing very low doses of synthetic progestogen. They prevent pregnancy 
by thickening the cervical mucus and, sometimes preventing ovulation(Amy 
& Tripathi, 2009).POP can be an alternate option for women who want to use 
oral contraceptives, but cannot use COC (de Melo, 2010).5ome mood changes 
with POPs (particularly, those with Levonorgestrel) have been reported 
(Lakha et aL, 2007) and irregular bleeding as a side effect (de Melo, 2010). 
Injectable Progestogens 
There are two injectable Progestogen contraceptive preparations: Depo-
Provera® (DMPA 150 mg) which is given every twelve weeks (Hatcher et aI, 
2008), and Nurlsterate ® (Norethisterone Enanthate 200 mg or NET-EN), 
given every eight weeks and which is effective for a shorter period than 
DMPA (Rivera, Yacobson & Grimes, 1999). 
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These two injectable have been in existence since the 1960's (Kaunitz, 
2(01).At the time of writing, DMPA and NET EN are the most common 
contraceptives used in South Africa (Department of Health, 2012; Mghayi et 
aL, 2004).About 80% of contraceptive users in South Africa are on 
progestogen injectable contraception (Ortayli, 2006). 
Injectable progestogens have several mechanisms of action for preventing 
unintended pregnancy including, blocking ovulation, thinning the lining of 
the uterus, and thickening cervical mucus to act as a barrier to sperm. (Haider 
& Darney, 2007; Hatcher et aL, 2008; Kaunitz et al., 2009). 
Advantages and disadvantages of injectable Progestero1lc contraceptivcs 
There is general consensus in the literature that DMPA is highly effective as a 
contraceptive, and convenient, as only needs to be administered once in ] 2 
weeks (Burke, 2011; Draper et aL, 2006; Haider & Darney, 2007; Hatcher et 
aL,2008). 
The DMPA pregnancy rate was found to be 0.3 % with perfect use and 3% 
with typical use (Trussell, 2004). It is probable that pregnancy rates decrease 
with duration of use (Kaunitz et aL, 2009). 
DMP A effectiveness is independent of daily intervention as it is for the oral 
contraceptive as discussed in the previous section. In addition to these other 
advantages DMPA can be used in various conditions, where there is a 
contra-indication to estrogen, i.e. coronary artery disease (Guilbert et al., 
2009).It has the non-contraceptive benefit of decreasing the risk of 
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endometrial cancer (Thomas & Ray, 1991; Wernli et a1., 2006) ,iron deficiency 
anaemia(Cullins, 1996), and uterine Ieiomyoma's(Lumbiganon et a1., 1996). 
On the other hand, injectable progestogen has disadvantages, which may 
lead to discontinuation and thus unintended pregnancies. In a Cochrane 
systematic review conducted by (Draper et aI., 2006), the rate of 
discontinuing injectable methods within 12 months was found to be 49% for 
DMPA, and 48% for NET ET. The main rt'ason given for discontinuation was 
menstrual disturbances (Draper et aI, 2006).5imilarly, in a retrospective study 
that was conducted in Iran more than eight hundred previous DMPA users, 
(41.3%) discontinued after the first injection and 19% discontinued after the 
second injection. Menstrual disturbances were the primary reasons for 
discontinuation(Adeyemi & Adekanle, 2012; Hajikazemi, Nikpour & 
Haghani, 2004; Wood & Jewkes, 2006).Vaginal estrogen supplementation 
during DMPA initiation may reduce the risk of irregular vaginal bleeding 
(Dempsey, Roca & Westhoff, 2010). 
In a systematic review of a hormonal implant (LNG implant) and DMPA 
(Hubacher et al., 2009), 12% of 1610 DMPA users had amenorrhea compared 
with 11 % of 1629 LNG implant users in the first 90 days of use (Hubacher et 
aI., 2009). 
DMPA has been reported to cause weight gain in users(Haier & Draney, 
2007; Nitrate, Abash & Shaffer, 2013; Vickery et aI., 2013; Westhoff et aI., 
2007b)A study by (Beksinska et aI., 2010) of new adolescent users of 
hormonal contraception, non-users and discontinuers reported that weight 
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gain among injectable contraceptive users was more than twice that of other 
methods(Beksinska et a1., 2010).Without ready access to alternative methods, 
many women feel compelled to continue with a method they are not happy 
with, or to stop contraceptive use altogether(Gilliam et al., 2004). 
There are some controversies around initiation of hormonal contraception 
before 6 week postpartum in breastfeeding mothers and WHO made a 
recommendation that DMPA and NET-EN can only be used before 6 weeks if 
other methods are not available (WHO, 2009). But report from other 
researchers is reassuring that they could not establish negative effects of 
hormonal contraceptive on lactation (Espey et al., 2012; King, 2007; Truitt et 
al., 2009).1n the South African guidelines (Department of Health, 2012), 
there is no restriction of the use of progestogen only contraceptives therefore 
the use of DMPA in this study was possible as it is routinely administered to 
women before they are discharge postpartum(Hani et al., 2003; Peltzer, Chao 
& Dana, 2009). 
One other controversy about hormonal contraception is an association with 
HIV transmission and disease progression (Baeten, Lavreys & Overbaugh, 
2007; Heffron et al., 2012; Morrison & Nanda, 2012; Polis et al., 2011). In a 
Cochrane systematic review that compared contraceptive and non-
contraceptive benefits and risks of using DMP A as compared with Cu IUD 
(Hofmeyr, Singata & Lawrie, 2010) HIV disease progression was increased in 
the depot progestogen group{RR 0.58;95%CI 0.39 to O.87).Mixed hormonal 
contraceptives were used in Stringer (1997), RCT that was included in the 
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mOfe C<>Tlfirmatiun frolIl(Cmtis, t\~n,Ja & Kapp, 200Y; Polis, Phillips & 
Curl'~, 2013) . 
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pop, Pwgestogen only pill; COC: Combined oral contra.:eptive pills; JUS, 
Intrauterine system; IUD; lnrmutl'l"im.' contraceptive de,-ice_ (Flemmg, 2009) 
2.8.4 Abortlon 
When services for family pJanninli are not available to young adults and 
women and in &ituations wheT€ there are barriers to accessl11g U,.,,,,, sefvicL,,", 
some wolYl<Cn resort to abortion (M'lhayi et aI., 20(4)- Abortion JS Ihe 
tennination of pT€gnancy and, in must situations, the pregnancy is 
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unwanted. An estimation of 45.8 million abortions occurred in 2008 
worldwide (Sedgh et al., 2012), nearly half of which are reported to be unsafe 
(World Health Organization, 2012).In South Africa there has been a growing 
need for termination of pregnancy services (Cooper et al., 2004). 
Women who resort to terminating an unintended pregnancy have been 
shown to be more able to protect their education opportunities (Fergusson, 
Boden & Horwood, 2007).5outh Africa is one of the countries where abortion 
is legalised, however, abortion is also viewed as a non-Godly act (Patel & 
Kooverjee, 2009) and some religions are completely against termination of 
pregnancy, advocating for pro-life (Ellison, Echevarria & Smith, 2005). 
2.9 Summary of chapter 
This chapter has explored the contexts in which this study is taking place on. 
Different methods of family planning and contributory factors to 
contraception non-use have been discussed. DMP A and Cu IUD advantages 
and disadvantages have been explored. 
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Chapter 3: Depression and Sexual Functioning 
3.1 Introductioll 
This chapter is divided into two sections. The first section explores literature 
on depression and, in particular, postpartum depression (PPD).Included are 
the prevalence of PPD in low and middle income countries, and risk factors 
of PPD, and the effects of PPD on both mother and baby are discussed. The 
second section explores literature on sexual functioning, different sexual 
response cycles, and sexual dysfunction during the postpartum period, and 
the potential effects of contraception on sexual functioning. 
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3.2 Depression 
3.2.1 Prevalence of Depression 
According to the national representative survey which was conducted 
between 2002 and 2004, the lifetime prevalence of major depression in South 
Africa is 9.8% and the twelve month prevalence is 4.9% (Tomlinson et al., 
2009). 
In comparison, the prevalence estimates for a major depressive episode 
(MOE) of 10 developing country populations (Belgium, France, Germany, 
Israel, Italy, Japan, Netherlands, New Zealand, Spain and America) are 14.6% 
and 5.5% for an average lifetime prevalence and twelve month prevalence, 
respectively (American Psychiatric Association & American Psychiatric 
Association. Task Force on DSM-IV., 1994; Bromet et a1., 2011).Postpartum 
depression presents in the same way as major depression; the only difference 
is the timing of the occurrence of symptoms of depression (Najman et al., 
2000). 
Women are said to be twice as prone to depression as men, as shown by 
various studies conducted both internationally and in South Africa; 
Tomlinson males and females have sex hormones that may influence mood, 
however levels of these hormones differ. The dominating sex hormones in 
females are both progesterone and oestrogen (Douma et al., 2005). 
Postpartum depression presents in the same way as major depression, the 
only difference is the timing of the occurrence of symptoms of depression 
(Najman et al., 2000). 
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3.2.2 Postpartum depression 
Postpartum depression (PPD), also known as postnatal depression, is a 
psychological disorder that occurs after childbirth (American Psychiatric 
Association & American Psychiatric Association. Task Force on DSM-IY., 
1994). It frequently begins with postpartum 'blues', a condition that presents 
with weeping, sadness, uncontrolled and depressed mood, irritability, 
anxiety and sleeplessness(Alici-Evcimen & Sudak, 2003).These signs 
frequently occur around the fourth day after childbirth and the mother's 
condition gradually improves by the tenth day (Alici-Evcimen & Sudak, 
2003). 
According to the Diagnostic and Statistical Manual of mental disorder's 
(DSM-IV), when postnatal blues does not improve within four weeks of 
childbirth it is then defined as postpartum depression. For postpartum 
depression to meet the criteria of major depression, depressed mood, or loss 
of interest or pleasure must be present for at least two weeks (DSM-IV, 
Pearlstein Teri, 2008). According to the International Classification of 
Diseases version 10 (ICD-I0) postnatal depression is defined six weeks after 
childbirth (World Health Organization, 1992). 
During the postnatal period, women appear to be more vulnerable to 
depression (Douma et al., 2005; Kessler, 2003) Several risk factors for PPD 
have been documented, including: a history of depression (both postnatal 
and non-postnatal)(Alici-Evcimen & Sudak, 2003; Henshaw, 2003); a family 
history of mood disorders(Milgrom et al., 2008); estrogen deficiency, poor 
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pregnancy outcomes, societal stresses, and stressful life events (Ramchandani 
et a1., 2009); and a poor marital relationship(Alici-Evcimen & Sudak, 2003; 
Cooper et a1., 1999; Milgrom et a1., 2008; Ramchandani et a1., 2009; Rich-
Edwards et a1., 2006). 
3.2.3 Prevalence of postpartum depression 
Halbreich and Karkun (2005) reviewed 143 studies from 40 countries 
reporting PPD prevalence and found much variation, with PPD prevalence 
ranging from 0% to 60%. Although the overall global prevalence of PPD was 
considered to be 10 to 15%, these authors considered this not to be globally 
representative due to the wide variability between countries. 
The prevalence of PPD in South Africa is considered to be between 20 and 
29% (See Figure 4; Parsons, 2012). In a South African study conducted in 
1998, the Edinburgh postnatal depression scale (EPDS) was used to identify 
women at risk of PPD (defined by an EPDS score> 11). Thirty-six percent 
and 31 % of the study sample (163 women) had EPDS scores> 11 at six weeks 
and three months after delivery, respectively. Similar rates of PPD were 
reported (34.7%) in an observational study by Cooper and colleagues (1999) 
conducted in Khayelitsha Township, Cape Town, was reported in a sample 
of 147 women using the DSM-IV diagnostic tool to diagnose major 
depression (Cooper et aI., 1999). In the latter study, the majority of 
participants were Xhosa speaking, similar to participants of this study. 
Recruitment took place over nine months period and selection of the 147 
participants were from a community of ± 329 002 (Statistics South Africa, 
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According to the above map (figure 4) prevalence of PND in South Africa is 
said to be 20% (Parsons et a1., 2012). 
3.2.4 Oral contraception and depression 
Various researchers have raised concerns about the lack of strong evidence to 
show a causal effect of oral contraception on depression (Duke, Sibbritt & 
Young, 2007; O'Connell, Davis & Kerns, 2007b; Toffol et aI., 2011). 
Robinson et al (2004) conducted a literature review of seven studies in an 
attempt to demonstrate association between the intrinsic pharmacologic 
properties of the oral contraceptive pill and mood disturbances. The authors 
assert that the collective data demonstrated that hormonal contraceptive 
users, in contrast with non-users, have higher rates of depression, anxiety, 
fatigue, neurotic symptoms, sexual disturbances, compulsion, anger, and 
negative menstrual effects. They argued that the cause was a psychological 
and not pharmacological effect (Robinson et a1., 2004). 
3.2.5 Injectable hormonal contraception and depression 
In a randomised study of subcutaneous DMPA versus intramuscular DMPA, 
depression was measured using a patient satisfaction questionnaire (PSQ) 
(Kaunitz et a1., 2009). Authors concluded that DMPA was not a causal factor 
for depression as the study incidence of depression was similar to that found 
in a cross-national epidemiological data of major depression and bipolar 
disorders conducted from 10 countries (Weissman et a1., 1996). 
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The findings of Gupta et al., 2001 support the Kaunitz study. In this 
prospective study conducted in the USA, mood changes were assessed in 
adolescents using contraception in Boston. The sample size for Gupta's study 
was 53 and participants were not randomised. The 39 participants that chose 
DMP A as a method served as the experimental group and 24 that did not use 
DMP A served as the control group. Participants were followed up for 12 
months. The authors reported that the mean depression scores of the 
experimental and control groups did not differ significantly (Gupta et al., 
2001). However the two groups in this study had many differences at 
baseline (more adolescents in the DMPA group were poor academic 
achievers, had previously been pregnant and had a history of receiving 
psychological counselling) and the study methodology did not control for 
these confounding factors. 
Another study conducted in the USA has also reported no differences in 
depression scores of DMPA users of a high risk population (Westhoff, 
Wieland & Tiezzi, 1995). In this study, participants were invited to 
participate by study clinicians after being identified from the clinic records. 
To meet the inclusion criteria, women had to be English speaking. A total of 
80 women were enrolled. These authors reported no difference in the 
Community Epidemiology Survey-Depression scale (CES-D) score at high 
exposure of DMPA versus low exposure. The results of this study are limited 
by the absence of a control group and the small sample size. 
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Another American study conducted by Westhoff et al (1998) found that more 
than 50% of DMPA users who discontinued the method had higher 
depression scores at baseline than continuers (Westhoff et al., 1998). 
Civic and colleagues assessed depression symptoms in 457 users and non-
users of DMPA, in a study in which the primary outcomes was bone density 
evaluation. Depression scores measured by the CED-S were assessed in 180 
DMP A users and 257 non-users. No explanation is given about how 
participants were allocated to study groups. DMPA users who continued 
with the contraceptive method were 40% more likely to report depressive 
symptoms and 60% of DMPA users who discontinued were more likely to 
report depression symptoms than the non-users (Civic et al., 2000). This 
study lacked controlling for confounding factors in their groups and 
therefore it is difficult to be certain if DMPA was the cause of depression or 
not. 
3.2.6 DMPA and postpartum depression 
The postpartum period is a very critical period not just for the mother but for 
the baby as well. It is important to identify women who are more vulnerable 
to PPD so that prevention measures can be taken. 
Evidence for an association between progestogen contraception and PPD is 
limited and conflicting. In a South African double-blind placebo-controlled 
study, the injectable progestogen contraception NurIsterate® (Norethisterone 
Enanthate) was associated with increased risk of PPD and reduced serum 
estradiol and progesterone levels when used during the postnatal period 
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(Lawrie et aI, 1998). In this study of 180 women, mean depression scores for 
the progestogen group were significantly higher than those of the placebo 
group (Lawrie et al., 1998b). 
A retrospective review was conducted of the clinic records of 55 DMPA users 
and192 women not using hormonal contraception at their six week postnatal 
check-up(Tsai & Schaffir, 2010). EPDS scores were compared and found to 
be not significantly different between the groups. Ten percent of the DMPA 
users and 14 % of the non-users had PPD defined as an EPDS score of >13 (P 
= 0.88). However, these results of this study are limited by the design and the 
potential of confounding factors, e.g. the women in the DMPA group were 
significantly older that the group do non-users. 
To the researcher's knowledge, there have been no studies randomizing 
women to DMPA or non-hormonal contraception to evaluate the effect of 
DMPA on depression and sexual functioning. Therefore, the design of this 
study is unique (randomising research participants to either DMPA or the 
copper IUD, and aims to address the limitations of the existing evidence. 
3.2.7 Effects of Postpartum depression 
Cooper and colleagues in their study conducted at the Khayelitsha Township 
(South Africa) on mother-baby pairs showed that major depression had a 
negative effect on bonding between mother and baby (Cooper et a1., 1999). 
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Similarly, negative effects were reported in an Indian study (Patel, DeSouza 
& Rodrigues, 2003). The aim of this study was to determine whether PPD 
contributes to poor growth and development of the infant. They found that 
PPD was a contributing factor to poor growth and development of babies 
born to depressed mothers (Patel, DeSouza & Rodrigues, 2003). 
3.3 DMPA and Sexual Function 
It is important to understand normal female sexual function to determine 
whether contraceptives have an effect on sexual functioning or not. 
Meston & Buss (2007) conducted a study to understand why human beings 
engage in sexual intercourse (Meston & Buss, 2007). However, there are 
many other factors positively and negatively that can affect sexual 
functioning such as environmental, cultural, religious and societal norms. 
With the help of an existing sexual functioning model researchers and 
clinicians can identify factors that can cause variation in sexual functioning 
(Richard D. McAnulty, M. Michele Burnette, 2006). In addition phases of 
human sexual response to be discussed in this chapter will help to 
understand normal sexual function as opposed to sexual dysfunction 
(Davison et aL, 2008). 
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3.3.1 Sexual Functioning. 
Kaplan defines sexual function as an emotional ability to experience desire 
(Kaplan, 1974), arousal and orgasm with a requirement of the integrity of 
genitalia reliable co-ordination of blood flow (Munarriz et aI., 2002) 
Different scientists have developed sexual response stages models(Basson, 
2000;Kaplan,1974), and all have evolved from the traditional model 
developed by Master and Johnson in the 1960's with phases of "sexual 
excitement, plateau, orgasm and resolution" (Masters & Johnson, 1966). 
Masters and Johnson developed the sexual response model after laboratory 
observations of 700 men and women masturbating and engaging in sexual 
intercourse. Master and Johnson's model suggests that the sexual response 
phases are linear meaning that the sexual desire phase always comes before 
arousal phase. Furthermore "excitement" in Masters and Johnson's model is 
said to be the first phase of sexual response. 
On the other hand Kaplan developed a model that contradicted the Master 
and Johnson's model with the hypothesis that before sexual intercourse one 
should have a desire to do so and Kaplan produced a sexual function 
response cycle that has three phases: desire, arousal, and orgasm (Kaplan, 
1974). 
After Kaplan's model researchers still felt there was a need for another model 
that could explain norma] sexual response in women (Basson, 2000; Whipple 
& Brash-McGreer, 1997). Whipple and Brach-McGreer developed a circular 
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McGahuey and colleagues reviewed studies that identified some core 
elements of sexual function and they produced the following phases U sex 
drive, arousal, penile erection/vaginal lubrication, ability to reach orgasm 
and satisfaction" (McGahuey et al., 2000). McGahuey and colleagues then 
developed a sexual functioning scale called the Arizona Sexual Functioning 
Scale (ASEX) to quantify the sexual responses and to measure sexual 
functioning. The ASEX is one of the instruments to be utilised to measure 
sexual function of women participating in the study. 
Sexual desire is a drive or interest to have sexual experience with or without 
a partner(McGahuey et a1., 2000).Neurotransmitters, sex hormones and 
environmental factors are said to have an influence in sexual desire (Basson, 
2006).In an observational study that was conducted by Basson in Vancouver 
(Canada) the majority of women who had sexual desire dysfunction 
expressed insufficient emotional intimacy and factors involve stimuli as 
contributory factors to their problem(Basson, 2000).However, there is poor 
evidence to support factors that can affect sexual desire Basson have then 
advocated for randomised control trial to assess the effect of psychological 
and pharmacological therapies for sexual dysfunction. 
It is very important to note that there is a difference between sex desire and 
sexual arousal and it does not mean arousal takes place after sexual 
desire(Basson, 2000).Graziottin defines sexual arousal as U a state with 
specific feelings attached to the genitalia" (Graziottin, 2000). Graziottin's 
definition indicates that there is some visible biological changes in the genital 
65 
area during sexual arousal. Engorgement of the labia's and clitoris as they 
are filled up with blood and this elongates the vagina (Meston et al., 
2004).Lubrication or vaginal wetness is also evident at this phase of sexual 
response (Basson, 2005). 
Orgasm is a phase in sexual response that manifests itself as an intense 
pleasure reaching the climax of excitement during sexual intercourse, which 
varies in individuals and women (Meston et aL 2004). 
3.3.2 Sexual Functioning after childbirth 
In a study (Leite et al., 2009) that observed a group of pregnant teenagers and 
adults who were 20 years or more sexual function during the third trimester 
has been reported to have declined, with adults having higher sexual 
dysfunction than teenagers. Several researchers have studied return of sexual 
interest or vaginal intercourse after birth (Ezebialu & Eke, 2012; Hicks et al., 
2004; von Sydow, 1999).In the Nigerian study by Ezabialu and Eke only 
29.7% had a return of sexual interest/intercourse at 6 weeks postpartum. 
Researchers have studied the effect of mode of delivery on sexual function 
with contradictory results reported(Baksu et al., 2007; Hicks et al., 2004; 
Safarinejad, Kolahi & Hosseini, 2009).A study conducted in Sweden on 
women who asked for elective caesarean section without any medical 
indication compared with elective vaginal delivery reported no difference in 
the two groups in sexual function at three months postpartum(Wiklund, 
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Edman & Andolf, 20(7).5imilarly Safarinejad, Kolahi & Hossein reported in 
their study that women post caesarean section had a higher quality of life 
than women who delivered by other means. On the other hand Basku et al 
(2007) reported a negative effect of vaginal delivery with episiotomy on 
sexual functioning associated with increased level of pain at 6 months as 
compared to the caesarean group. Literature review with no meta-analysis 
by Hicks et al (2004) of 6 studies conducted in developed countries also 
associated assisted vaginal delivery with some degree of sexual dysfunction. 
3.3.3 Sexual functioning and Intra-uterine device - Copper T380A 
A study that was conducted in Turkey to examine the effects of family 
planning methods reported that IUD users expressed no change in their 
sexual lives(Gabalci & Terzioglu, 2010).However in their study ASEX score 
for sexual satisfaction was 13.32 and for sexual desire 13.21 showing sexual 
dysfunction according to their cut off contrary to the cut off for sexual 
dysfunction given by the producer of ~19 (McGahuey et al., 2000). 
3.3.4 Hormonal contraception and sexual functioning 
Substantial research (Caruso et al., 2004; Gabalci & Terzioglu, 2010; Greco et 
al., 2007; Sabatini & Cagiano, 2006; Schaffir, Isley & Woodward, 2010a) has 
been conducted on the effect of combined oral contraceptive pills and sexual 
functioning, research reports are discussed below. 
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Gabalci & Terzioglu, (2010) surveyed differences in sexual experiences for 
users of different types of contraception, i.e. condoms, withdrawal, IUD and 
oral contraception. In their study, 366 Turkish women were interviewed 
(Gabalci & Terzioglu, 2010). Although participants of the study generally 
reported sexual concerns, there were no significant differences between users 
of hormonal and non-hormonal contraception (Gabalci & Terzioglu, 2010). 
Similar results of the Turkish study have been reported in Chinese women of 
whom no statistical difference was reported from baseline and at four 
months follow-up(Li et al., 2004). 
A study that assessed combined oral contraceptive and injectable progestin 
(DMPA) effects on sexual function (Schaffir, Isley & Woodward, 
2010b),showed a difference in the level of free testosterone in cac group 
having lower levels of free testosterone compared to the DMPA group and 
cac group had lower levels of estradiol. However there was no significant 
difference in the two groups' sexual function regardless of the difference in 
androgen levels (Schaffir, Isley & Woodward, 2010b). 
In contrast, Robinson et. al. (2004) reviewed over seven studies to ascertain 
whether emotional side effects of hormonal contraceptives were due to 
pharmacological or physiological causes. Their findings revealed that causes 
of side effects were due to physiological and not pharmacological effects of 
the hormonal contraceptives. However, no meta-analysis was conducted as 
part of their review and the studies that were reviewed were conducted 
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between the 1960's and the 1980's, however the hormonal contraceptive used 
during that time had lower levels of ethinyl estradiol (Robinson et al., 2004). 
On the other hand (Sabatini & Cagiano, 2006) on their comparison of side 
effects of three hormonal contraceptives, (20 pg of ethinylestradiol (EE)/100 
of Levonorgestreol and 15 pg of EE/60 pg of gestodene) compared with 
vaginal ring (15 pg of EE/120 pg of etonogestrel) found negative influence 
on sexual desire due to vaginal dryness (Sabatini& Cagiano, 2006). 
3.3.5 DMPA - Sexual functioning 
DMPA use for treatment of male sexual offenders has been reported to 
decrease sexual drive (Kiersch, 1990) 
Kaunitz and colleagues (2009) on their study of subcutaneous DMPA as 
compared to intramuscular DMPA reported decreased libido as an adverse 
event. Similarly low libido among DMPA users was reported by (Matson, 
Henderson & McGrath, 1997; Paul, Skegg & Williams, 1997). 
Berga & Smith alluded to interference of DMPA on sexual interest and 
generalised that progestin diminishes libido and sexual responsiveness 
(Berga & Smith, 2012). 
3.4 Summary 
Prevalence of major depression in South Africa is 9.8% and 4.9% for the 
twelve months prevalence as compared to the estimates from the developing 
countries which are 14.6% and 5.5% for an average lifetime prevalence and 
twelve months prevalence. 
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Several risk factors for postpartum depression have been documented; 
family history of mood disorders, estrogen deficiency and poor pregnant 
outcomes. The prevalence of PPD in South Africa is said to be between 20 to 
29%, though from low and middle income countries it's given to range from 
0% to 50%. 
Evidence to associate oral contraceptives with depression in various settings 
is lacking. However progestogen contraceptive use in the postpartum period 
has been associated with depression in only one study. 
Postpartum depression has showed to have an adverse effect on bonding 
between mother and baby and it is reported to contribute to poor growth and 
development of babies born to depressed mothers. 
A decline in sexual functioning after childbirth have been associated the 
mode of delivery (operative/assisted deliveries); old age also was another 
factor that influence sexual functioning. 
Majority of oral contraceptives studies could not find a statistically 
significant effect of OC no sexual dysfunction. 
The DMPA has showed to decrease sex drive when used to treat sexual 
offenders. Report from observational studies has associated DMPA use for 
contraception with low libido. 
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Chapter 4: Methodology 
4.1 Introduction 
The chapter presents the hierarchy of study designs that led to the need to 
the selection of a randomised controlled trial methodology to conduct this 
study. It describes the study design, research sites, study population, sample 
size calculation, inclusion and exclusion criteria, recruitment and 
randomisation procedures and the instruments for data collection. It also 
describes the results of the pilot study. In addition, this chapter includes the 
methods for determining validity and reliability of the instruments, data 
collection, ethical considerations, data management and analysis. Finally, the 
chapter explains the risks and benefits of taking part in the study, and the 
referral system put in place to support study participants. 
4.2 Research Questions 
This study posed the following research questions: 
• Are there statistical differences in the effects of injectable DMPA on 
postpartum depression as compared with the Cu-IUD (Copper T 
380A) as measured with EPDS and BDI-II? 
• Are there statistical differences in the effects of injectable DMPA on 




4.3.1 Null hypotheses 
• There is no statistical difference in the rates of postpartum depression 
between women using the IUD (Copper T 380A) and those using 
injectable DMPA contraception in the Eastern Cape. 
• There is no statistical difference in sexual functioning between women 
using the IUD (Copper T 380A) and those using injectable DMPA 
contraception in the Eastern Cape. 
4.3.2 Alternate hypotheses 
• The use of injectable DMPA, given to women of reproductive age who 
wish to practice birth control, will result in a statistically significant 
difference in the level of depression compared to women who 
received the Cu-IUD. 
• The use of injectable DMPA, given to women of reproductive age who 
wish to practice birth control, will result in a statistically significant 
difference in the level sexual functioning compared to women who 
received the Cu-IUD. 
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4.4 Research Design 
4.4.1 Quantitative design 
The research approach in this study is an experimental quantitative 
approach. Ponterotto (2005) describes quantitative methods as having a 
" .. .focus on the strict quantification of data and on careful control of 
empirical variables" (Ponterotto, 2005). Lietz and Zaya, (2010) describe the 
purpose of quantitative research as seeking". Through measurements to test 
a hypothesis, to determine outcomes and to draw generalizable conclusions 
to a defined population" (Lietz & Zayas, 2010). 
Experimental study designs focus on testing causality with optimal control. 
A type of experimental study design is the randomised clinical trial (ReT) 
which is used in this study. 
Filstead (in Ponterotto, p.127-128) defines a research model as ... a set of 
interrelated assumptions about the social world which provide a 
philosophical and conceptual framework for the organised study of that 
world" (Filstead, 1979; Ponterotto, 2005). 
Post-positivism stresses objectivity, experimentation and generalizability 
(Mertens, 2(10).Objectivity, experimentation and generalizability support the 
generation of meaningful and relevant knowledge for action, which was the 
paradigmatic intent behind this research project. The selected paradigm will 
inform on selection of tools, instruments, participants, and process of this 
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4.4.3 Advantages and disadvantages of RCT design 
RCT methodology makes it possible to allow. control of confounding factors 
is important to be able determine whether the intervention is the causal effect 
as compared to the control (Jepsen et al., 2004; Kendall, 2003).Control of 
confounding factors is achieved in RCTs by eliminating bias in method 
assignment(Schulz & Grimes, 2002). According to Schulz (2002), it then 
permits the use of probability theory to express the likelihood that any 
differences in outcome between treatment groups merely indicate chance. 
Non-randomized study designs such as case-control or observational studies 
cannot control for unknown confounding factors. 
4.5 Research sites 
The study will be conducted in two tertiary government hospitals that are 
23km apart, namely, Cecilia Makiwane hospital located in Mdantsane 
township(/native units" built by the apartheid government to house 
Blacks)of East London, and Frere Hospital situated near the central business 
district (CBD) of East London. Both hospitals have research and diagnostic 
facilities for conducting the study. The author of this document has the 
added advantage of access, as she had been working in both hospitals as a 
midwife-researcher for twelve years. 
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4.6 Study population 
Pregnant women (99% Black Xhosa- speaking) were enrolled and invited to 
participate in the study immediately after childbirth. Whilst still in hospital 
and prior to discharge. The population for this study was recruited from 
women who gave birth between 06 December 2012 and 30 March 2013. 
Participants for this study had to be of reproductive age (WHO).The eligible 
age to participate was between 18 and 44 years, as 18 years of age is the 
minimum age of consent for research participants (World Medical 
Association, 2008). 
4.7 Pilot study 
A pilot study was conducted with ten (10) postpartum women who 
consented to participate. And women approached consented to take part. 
Random allocation of participants to either OMPA or IUD was mostly 
welcomed by participants. One participant requested to consult her husband 
after consenting and before IUD insertion and this resulted in non-adherence 
to the allocated method. 
A copy of the study instruments, i.e. EPOS, BOI-II and ASEX was given to all 
pilot participants at enrolment to refer to during telephonic interviews. All 
participants were able to answer the questions with ease. Telephonic 
interviews were feasible and all participants were reachable. 
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4.8 Sample size calculation 
Two studies similar to the current study were identified during literature 
review. The first was a South African study by Lawrie et al (1998) that 
explored the effect of Norethisterone Enanthate (NET-EN) on PPD and 
serum hormones. Study instruments used to measure the primary outcome 
(PPD) was the Edinburg Postnatal Depression Scale. The mean depression 
score at six weeks was 8.3 [SD 7.5] for the NET-EN group. For the control 
group the mean depression score was 4.9 [SD 7.5]. The second study of 
(Gupta et aL, 2001 )that looked at the mood changes in adolescents using 
DMPA for contraception in this study the mean BDI scores for the DMPA 
group at three months was 11.5 (SD 10.2) and for the control group mean 
was 6.9 (SD 6.5). 
STAT A statistical software (StataCorp, 2011) was used to calculate sample 
size. Based on these previous studies, we calculated our sample size as 
follows: To be able to show a reduction in mean depression score from 11.5 
to 6.9, s 73 women were required in each group (alpha = 0.05, beta= 90%). To 
allow for 25% loss to follow-up, the sample size was increased to 200.The 
sample size was further increased as there was an unexpected lack of 
adherence to one of the study methods (IUD) due to requests to postpone 
insertion by participants after randomisation. The required sample size was 
increased to allow for some non-compliance, which might have reduced the 
power of the trial. Finally, a total of 242 women were included in this study. 
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4.8.1 Inclusion criteria 
Inclusion criteria for women to participate in this study: 
• Child bearing women between the age of 18-45 
• Child bearing women with no contraindications to either method 
(World Health Organisation, 2009). 
• Child bearing women willing to use either DMPA or IUD within 48 
hours of childbirth. 
• The women must consent in writing to participate in the study. 
• The women should be able read English and/ or Xhosa 
4.8.2 Exclusion criteria 
• Women with severe depression defined as a BDI score of 29-63 (Beck, 
Steer & Brown, 1996). 
• Women with no access to a telephone. 
• Women who have delivered >48 hours will be excluded as IUDs 
inserted in the puerperium must be inserted within 48 hours of 
childbirth (World Health Organisation, 2009). 
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4.9 Recnlitment procedures 
Gross and Colleagues, (2002) and Wright, (2006) referred to participant 
recruitment as a process of identifying a target population, reviewing 
eligibility criteria, and obtaining consent to assemble a study population 
(Gross et aI., 2002; Wright, 2006). 
Selection of potential participants was based on the antenatal records from 
the two hospitals. The Effective Care Research Unit (ECRU) trained 
field workers were responsible for distributing information leaflets to the 
pregnant wow omen in the two hospitals. Once the women had read the 
information leaflet and agreed to take part in the study, the fieldworkers 
then referred them to the research-midwives for screening to determine 
eligibility. 
If eligible, pregnant women were given further details about the study and 
invited to participate. Those willing to participate signed the Information 
and Consent Form. A photocopy of the signed Information and Consent 
Form was given to each participant for their personal record (Appendix A 
&B).Copies of the EPOS (Appendix 0), BOI-II (Appendix E or F)and ASEX 
(Appendix G)instruments were given to participants to take home to read as 
the content would be the focus during the telephonic interviews after 
randomisation. 
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4.9.1 Role of the research midwives 
Enrolment took place prior to delivery. However, if participants underwent a 
caesarean section during which an IUD was inserted, they were excluded. 
Both participants and the researcher were blinded to the allocation sequence 
to prevent selection bias. The contraceptive methods were allocated to the 
woman by drawing the next in a series of consecutively numbered, sealed 
opaque envelopes containing allocation cards. The cards were in a computer-
generated random sequence in balanced blocks of variable size which had 
been prepared by the co-supervisor of the researcher and were packed in 
envelopes by the data manager of the Effective Care Research Unit based at 
Cecelia Makiwane Hospital. 
Screening, enrolment and baseline interviews were conducted by assisting 
research midwives; subsequent telephonic interviews were conducted by the 
principal researcher. Participants were requested during the informed 
consent process to keep the allocated method of contraceptive confidential 
during telephonic follow-up interviews at one month and three months to 
ensure the telephonic interviewer remained blinded to the allocated method 
(See appendix A&B). 
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Injectable progestogen group - (DMPA) 
The women were fully counselled on the use of injectable DMP A 
contraception, and the need for repeat injections at three monthly intervals, 
according to the WHO Family Planning Handbook for Providers (WHO, 
USAID, Johns Hopkins, 2012). The first injection was administered on the 
day of enrolment into the study by a midwife employed by the Eastern Cape 
government as a family planning provider in the postnatal wards. This 
midwife was aware of the study procedure and worked in consultation with 
the research midwife. All participating women were then referred to attend a 
designated appointment at their local clinic every three months for their next 
dose of DMP A. 
Cooper T 380 A- IUD group 
All participants allocated to the Cu-IUD group were counselled on the use of 
the Cu-IUD, according to the WHO Family Planning Handbook for 
Providers (WHO, 2012). A standard Copper T 380A IUD was inserted using a 
standard technique by an experienced doctor or midwife employed by the 
hospital, as would occur for any woman choosing this contraception option 
after delivery. Immediately after insertion, ultrasound was performed by a 
trained sonographer employed by the hospital to confirm placement. Study 
participants were asked to return to the Women's Health Clinic at each 
hospital for follow-up at six weeks to check the position of the Cu-IUD as is 
routinely practised at the two study sites. 
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4.10 Data collection 
Informed consent, demographic data, medical history, weight, and a brief 
questionnaire (see Appendix A) were obtained at baseline. In addition, all 
three study instruments (BDI-II, ASEX and EQ E5) were administered at 
baseline by research midwives in the form of a face-to-face interview; 
research midwives completed the study instruments. 
Women were followed-up telephonically after one month (high exposure of 
DMPA) and at three months (low exposure of DMPA), before the next 
scheduled injection (Westhoff et al., 1995). An interview schedule was 
arranged with each participant to be contacted telephonically. 
Participants were requested to be in a place where they will be comfortable 
to answer all questions to ensure privacy. The BDI-II was administered first, 
followed by the EPDS and the ASEX. During the interviews, the researcher 
read the questions, mostly in English, to the participants. Where necessary, 
the isiXhosa version of the BDI-II was used, and the EPDS was translated by 
the interviewer into isiXhosa and the respondent's reply recorded. 
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Table 1 : Data Collection instruments 
Time point in study 
Baseline / Screening Case Report Form BOI-II EPOS ASEX 
page 1& 
2(Appendix 3) 
One month Case Report Form BOI-II EPOS ASEX 
postpartum page 2 only 
telephone follow-up (Appendix 3) 
-
Three months Case Report Form BOI-II EPDS ASEX 
postpartum follow- page 2 only 
up (Appendix 3) 
4.11 Study instnl1nents 
4.11.1 Beck Depression Inventory (BOI-II) 
The Beck Depression Inventory was selected to evaluate depressive 
symptoms. It had been previously validated, used in the same cultural 
context and translated into the local language IsiXhosa (Somhlaba & Wait. 
2009; Segal, et al., 2008). 
English and IsiXhosa versions of the BOI-II were used in this study. The BDI-
II can be self-administered or verbally administered by a trained 
administrator. In this study, verbal administration was utilized during 
telephonic follow-up interviews (BOI-II®, Beck et al, 1996, Somhlaba & Wait, 
2009). 
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The BDI-II has 21 items, and each item is rated on a four-point scale ranging 
from 0-3. The maximum total score is 63 (Beck, Steer & Brown, 1996). 
According to the BDI-II manual, scores of 0-13 indicate minimal depression, 
scores of 14-19 indicate mild depression, scores of 20-28 indicate moderate 
depression, and scores of 29- 63 indicate severe depression (Beck, Steer & 
Brown, 1996). 
Approach used in this study: 
1. One copy was given to the participant at baseline and a research 
midwife explained the tool to the participant. Each question was read 
out by the midwife and an explanation was given where needed. The 
participant's response was recorded by the midwife. 
2. At one month and three months after baseline, follow-up telephone 
interviews were conducted by the researcher. Participants had copies 
of the questionnaires with them at home, whilst the researcher read 
out the questions and gave explanation where needed in the 
participant's language of choice: either English or IsiXhosa. Responses 
from the clients were recorded by the researcher on the Case Report 
Form (CRF) and measurement instrument (BDI-II). 
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4.11.2 Edinburgh Postnatal Depression Scale 
The Edinburgh Postnatal Depression Scale (EPDS) was developed by Cox 
(Cox, Holden & Sagovsky, 1987) and is used to screen postnatal depression 
globally. It is a 10-item self-report instrument where items are rated on a 
four-point scale to produce a summative score ranging from 0- 30. For this 
study, thresholds of 9 and 12 were used to indicate mild and severe 
depression, respectively. 
4.11.3 Arizona Sexual Experience Scale 
The Arizona Sexual Experiences Scale (ASEX) by McGahuey and Colleagues 
(McGahuey et a1., 2000) is used to evaluate sexual functioning. This is a five-
item rating scale instrument with total scores ranging from 5-30. It has been 
validated to be independent of the presence of a sexual partner (McGahuey 
et aI., 2000), and can therefore be used even when study participants are not 
sexually active. 
Among the measurement instruments researched, this scale was found to 
meet the needs of this study best because of its brevity and validity. Gabalci 
and Terzioglu (2010) in their study of the side-effects of family planning 
methods used this scale to identify sexual problems on their participants. 
These authors found the ASEX to be a useful, brief and simple scale. Other 
validated instruments used to measure sexual functioning were also 
reviewed by the researcher and found to be longer than the ASEX, with items 
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rangmg from 19-35 (Meston & Derogatis, 2002) as compared to a 5-item 
ASEX. As the ASEX only exists in an English version, the researcher 
translated it into IsiXhosa for those participants who did not understand the 
questions in English. 
Questions 4 and 5 of this scale are not ranked if a participant has not engaged 
in sexual intercourse within a week of the interview. 
4.11.4 Questionnaire 
A brief questionnaire was developed to collect, weight, medical and 
menstrual history, for comparison of other side effects as per the secondary 
objective and for eligibility screening (Appendix 3 case record form). This 
was a closed-ended questionnaire which covered all possible answers per 
question. The type of questions enabled the generation of numeric data. Page 
one of the questionnaire included eligibility check, medical and 
gynaecological history, and history of contraceptive use. On page two, data 
about HIV status, weight, menstruation, and feeding options used for the 
baby was collected. 
In addition some of the questions were taken from the EQ E5 (Jelsma et aI., 
2004) to collect demographic data of the participating women. 
4.12 Reliability and Validity 
Reliability refers to the degree of similarity of the information obtained when 
the measurements are repeated on the same subject or the same group 
(Katzenellenbogen et aI, 1997). Katzenellenbogen et aI, 1997 also define 
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validity as the extent to which a measure actually measures what it was 
meant to measure. 
4.12.1 One side blinded design 
The researcher administered the follow-up telephone interviews only and 
was not involved in screening and enrolment. The baseline screening for 
eligibility and enrolment was done by research midwives assisting in this 
study. The researcher only made contact with the study participants by 
telephone. 
The researcher remained blinded by reminding participants before the start 
of telephonic interviews not to mention the contraceptive method to which 
they had been allocated. The researcher was blinded to the allocated method 
until the end of the study. 
Blinding of the researcher in this study was done to reduce differential 
assessment of outcomes which is often called detection or ascertainment bias 
(Schulz and Grimes, 2002). 
4.12.2 The Beck Depression Inventory 
The Beck Depression inventory is widely used in South Africa both clinically 
and in trials (Lucas, September 2003; Somhlaba, Nceba. Z. & Wait,John. W., 
2009; Steele & Edwards, 2008). It has been translated into IsiXhosa, a 
language that is widely used in the Eastern Cape where this research was 
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conducted. (XBDI-Il, Steele, & Edwards, 2008. This IsiXhosa version has been 
validated and used by other researchers (Somhlaba, Nceba. Z. & Wait,John. 
W., 2009; Steele & Edwards, 2008). Steer et al. (2000) reported internal 
consistency of the BDI-II to be high with coefficient alpha = 0.90, and total 
score of BDI-II was not significantly related to sex, age, or ethnicity. 
4.12.3 Edinburgh Postnatal Depression Scale 
The EPDS has been validated in South Africa. Two studies have been 
conducted in two different sociocultural settings (Cooper et a1., 1999; De 
Bruin et al., 2004; Lawrie et al., 1998b) . 
Validation by Lawrie, Hofmeyr and de Jager (1998a) showed that EPDS was 
able to identify 100% of women with major depression and 70.6% with minor 
depression. Combined major and minor depression sensitivity was 80%, 
specificity 76.6%, positive predictive value 52.6% and the negative predictive 
value 92.2% (Lawrie et al., 1998a).De Bruin reported that the EPDS scores 
obtained from Xhosa speaking participants showed the EPDS to be reliable 
for this population (De Bruin et al., 2004). 
4.12.4 Arizona Sexual Experience Scale 
McGahuey and Colleagues conducted a study to validate and test reliability 
of the ASEX. They concluded that ASEX was a 'reliable, valid and a sensitive 
tool for measuring sexual dysfunction'. (McGahuey et al., 2000:35) 
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4.13 Ethical considerations 
Ethical approval was obtained before data collection began from the Faculty 
of Health Sciences Human Research Ethics Committee (FHS HREC: ref 
number 548/2012) of the University of Cape Town (Appendix 1), East 
London Hospital institutional Ethics Committee (Appendix J) and the 
Provincial Department of Health was requested for permission to conduct 
the study (Appendix K). This study adheres to the ethical principles outlined 
in the Declaration of Helsinki (World Medical Association, 2011) and the 
Constitution of the Republic of South Africa (Bill of Rights) (Devenish, 1999). 
Following a baseline screening at recruitment, participants who gave consent 
and who met eligibility criteria were allocated to either injectable DMP A 
(Depo-Provera®) or the Cu-IUD (Copper T380A®). As discussed in Chapter 
Two, hormonal contraceptives have been reported to have depressive and 
sexual function effects in some studies; therefore, the DMP A group was 
defined as the treatment (or experimental) group and the Cu-IUD group was 
defined as the control group. 
4.14 Informed consent 
All participants received information about the trial in the language of their 
choice, conforming to ethical requirements for research involving human 
subjects (Appendices A or B). Participant was given enough time to ask 
questions before obtaining a written confirmation of informed consent. 
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Participants were asked to sign informed consent to participate in the study, 
and were informed that they were free to withdraw from the trial at any 
stage without loss of benefits (Appendix A & B). 
4.15 Confidentiality and Anonymity 
Any information provided during the study by participants was kept 
confidential (Hewison & Haines, 2006). Full names do not appear on any 
study document, and only staff participating in the study had access to the 
information provided (Hewison & Haines, 2(06). 
4.16 Autonomy and Right to withdraw 
Participants were informed that they were free to choose whether they 
wished to participate (Appendix A & B). They were also free to withdraw 
from the study at any time should they have wished to for any reason. If for 
any reason they were not eligible for the study, or decide not to participate, 
they would still receive normal care. 
4.17 Possible risks/benefits from the research 
The study participants were informed of the possible risks and benefits of the 
methods of contraception used in this study. Both methods of family 
planning have risks and discomforts. 
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The discomforts associated with trial procedures included: 
• Completing of the questionnaires 
• Pain that might be felt during intramuscular injection administering 
the Depo-Provera 
• Pain that might be felt during insertion of the IUD. 
In case of adverse events that were reported or noted whilst 
subjects/participants were in the study (including depression and/ or sexual 
dysfunction), they were referred to the relevant health provider for the 
management. 
4.18 Data Management 
Data management consists of data preparation and processIng steps to 
produce clean data files (Stouthamer-Loeber & van Kammen, 1995). 
All study forms completed at baseline by research midwives were checked 
by the researcher for completeness and accuracy each day, before data entry 
onto Epidata statistical software (Lauritsen & Bruus, 2006).In Epidata, 
electronic data forms where created to be identical with the paper case report 
forms to prevent data entry errors and to save time. Two data capturers who 
had been trained by the researcher entered data. If there were any errors 
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picked up by data capturers, corrections were made before the second data 
entry. Double entry of data was done to detect inconsistency of data entry 
(Stouthermer-Loeber and van Kammer, 1995). 
The entered data was reviewed by the researcher for accuracy before 
unblinding the dataset by comparing the two data sets (decoding the 
randomized group). 
4.19 Data analysis 
Data was exported from Epidata into Microsoft Excel to enable import of 
data into Statistica (Statistica version 11).Before data was imported to 
Statistica it was cleaned and checked. Women were analysed in the group to 
which they were allocated, including those who did not receive the allocated 
method (intention-to-treat).Descriptive statistics were calculated for 
demographic data by the two treatment groups. The statistics included 
means, standard deviations, frequencies and percentages. Following are the 
procedures undertaken: 
Categorical data were compared as relative risks with 95% confidence 
intervals, using the Chi square test. 
For continuous data, the Shapiro Wilk test was used to test for normal 
distribution of selected variables (Altman DC, 1991). For normally 
distributed variables, the mean and the standard deviation were reported, 
and the t-test was done to compare the mean values and standard deviations 
for the two groups (Altman DC, 1999). For repeated measures (e.g. 
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depression score) at baseline, one month and three months, comparisons of 
one month and three month follow-ups against baseline were considered 
separately. 
a. For continuous variables: the baseline value for each subject was 
subtracted from the follow-up value (e.g. at one month) to 
calculate the change up to that time point. The mean values of the 
changes for each randomized group were compared using the t-
test and the mean difference with 95% CI (using RevMan 
software). 
b. For categorical variables, the baseline data were compared to 
confirm that the randomisation produced well-balanced groups. 
The follow-up variables were compared between groups using the 
chi-square test, as relative risks with 95% confidence intervals. 
If the continuous variables were not normally distributed, analysis was done 
with the non-parametric Wilcoxon test to compare median and Interquartile 
Range (IQR) of the two groups (Leedy & Ormrod, 2010). This followed the 
recommendation described by Altman (1991), that ".parametric methods 
require the observations within each group to have an approximately normal 
distribution and the standard deviation in each group should be similar. If 
the raw data does not satisfy these conditions a non-parametric method 
should be used". 
93 
4.20 Presentation of findings 
The risk of depression in the two groups is presented with a table and a 
forest plot to illustrate clearly any difference in risk of depression of the two 
groups. Both depression scales EPDS and BD1-1I are shown in one table, to 
highlight any differences in the results of the two depression scales. Three 
different tables are shown at each study point starting with baseline 
assessment, one month follow-up results and the three months results. 
Bar graphs present the different depression categories (mild to severe 
depression) in each chart for the three time-points. Each tool has its own bar 
chart. 
For sexual functioning a table with a forest plot will present the baseline, one 
month and three month follow-up results for risk of sexual dysfunction. Any 
difference between the groups should be easily visualized in this forest plot. 
Bar charts presenting events of sexual dysfunction by each item of the ASEX 
are shown. 
Secondary outcomes are presented in frequency tables so that the reader can 
see the actual number of events occurring in each group. 
4.21 Constraints and limitations 
Some eligible women who would have been enrolled in the study did not 
consent to participate as they did not wish to receive the IUD. The most 
frequent reason for this was a fear of pain during insertion, particularly in 
women who had experienced vaginal tears during delivery. 
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Follow-up at one month and three months was not possible during the day 
for all participants, as some were students and others were back at work. It 
was, therefore, necessary for the researcher to make some calls between Spm 
and 21hOOpm as per participant request. 
The study was expected to finish in June 2013, however, follow-up took 
longer than expected to complete. One participant, who was randomised on 
the 20th March 2013, was scheduled to go for a caesarean section on the same 
day, but the plan was changed and she was only delivered on the 11 th April 
2013. 
4.22 Summary of chapter 
The purpose of this chapter was to explain the research methodology of this 
study and to justify the research design and the strengths of the design 
chosen. Selection of participants and the study process were discussed. The 
statistical procedure used for the analysis of study data was described. 
95 
Chapter 5: Study Results 
5.1 Introduction 
This chapter presents the flow of participants through the study, baseline 
characteristics of the sample and the results of primary and secondary 
outcomes. 
5.2 Sample Description 
Participant flow from randomisation to analysis can be found in Figure 6, in 
accordance with the recommended CONSORT statement (Schulz, Altman & 
Moher, 2010). 
Recruitment commenced on the 04th of December 2012 and ended on the 20th 
March 2013. Follow-up continued until 1 July 2013. 
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(n= 51 
Both I month and 3 months f~low 
up was not acnieved 
The research midwives did not kept records of the number of women 
screened. However, based on hospital records, the number of women eligible 
for referral to the research midwives for screening from the two hospitals 
totalled to 575. 
As presented in the flow diagram (Figure 6), two hundred and forty-two 
(242) participants were randomly allocated to the study methods, i.e. 123 
were allocated to the IUD group and 119 to the DMP A group. 
There were eight exclusions from analysis; three were from the DMP A group 
and five from IUD group. All were excluded from the analyses as there were 
no data for both follow-up end points (1 month and 3 months). 
Adherence to the allocated method could not be achieved among all study 
participants. Three women in the DMP A group did not receive the allocated 
method because of reasons outlined in the flow diagram (Figure 6).Five 
participants in the IUD group refused insertion and one could not be inserted 
due to protocol violation because she was randomised three days after 
delivery (beyond the time-period for postpartum IUD insertion). 
Subsequently, this participant was given DMP A. Participants who did not 
receive the method they were allocated were still included in the analysis, 
with the "intention-to-treat" approach. 
After excluding eight participants from final analysis, a total of 234 
participants completed the study follow-up interviews and were included in 
the analysis (See Table 2). 
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5.3 Recruitment and follow- up 
Table 2: Recruitment and follow- up 
Baseline - BOI Baseline - EPOS Baseline ASEX 
Total = 234 Total = 234 Total = 234 
DMPA = 116 DMPA= 116 DMPA= 116 
IUD = 118 IUD = 118 IUD = 118 
One Month Follow- One Month Follow-up- One Month Follow-up 
up- BOI EPOS -ASEX 
Total = 228 (94 %) Total = 227 (93%) Total = 227 J93 %) 
DMPA=111 (93%) DMPA=110 (92%) DMPA=110 (92%) 
IUD=117 (95%) IUD=117 (95%) IUD=117 (95%) 
Three months Three months - EPOS Three months- ASEX 
follow-up: BOI 
Total = 230 {95%} Total = 229 (94 %) Total = 230 (95%) 
DMPA = 113 f94%1 DMPA = 113 (94%) DMPA = 113 (91 %) 
IUD = 117 (90%) IUD = 116 (94%) IUD = 117 (95%) 
Telephonic follow-up at one month after enrolment occurred at a mean of 34 
days. The second follow-up occurred at a mean of 90 days for the DMPA 
group and 89 days IUD group. Follow-up at one month was conducted 
telephonically for 225 participants and by home visit for two (2), which were 
done by a trained fieldworker, not the researcher. At three months follow-up, 
home visits were undertaken for 22 women (15 women on DMPA and 7 on 
IUD), and 208 were followed up telephonically. 
Overall, follow-up was 94% for one month and 95% for three months. There 
was no significant difference in achieved follow-up of groups at one month 
and three months. 
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5.4 Baseline results 
Baseline characteristics of participants are shown in Table 3.Data are 
expressed as frequencies (Percentages), mean [±standard deviation] and 
median [Interquartile range]. 
Table 3: Demographic and clinical characteristics of DMPA & IUD group at 
baseline. 
Characteristics Total DMPA IUD 
(N= 234) (N=116) (N= 118) P- value 
Medical and gynaecological history 
Age (medianl[IQR] 26[11-23] 26 [10-22] 26.5[11-22] 
Diabetics* 2(0.8%) 0 2(1.6%) p= 0.498 
High Blood pressure 16(6.3%) 8(6.7%) 8(6.7%) P=0.971 
Positive HIV+ ~(39%) 39 (33%) 52 (44%) P=0.102 
~-
CD4 count n=86 n=37 n=49 P=O.Ol** 
mean [SD] M385[177] M438[173] M344[170] 
Negative HIV- 141(60%) 75(64%) 66(55%) p= 0.173 
Previous pelvic sepsis 5(2.1 %) 2(1.7%) 3(2.5%) p=.9846* 
Spontaneous 13(5.5%) 6(5%) 7(5.9%) P=0.78 
miscarriages 
Previous C / S 19(8%) 11(4%) 8(6.8%) P= 0.45 
A current smoker 4(1.7% ) 3(2.5% ) 1(0.8%) P= 0.368* 
An ex-smoker 9(3.8%) 4(3.4 %) 5(4.2%) P=1.00* 
Never smoked 221(94%) 109(93%) 112(94%) P=0.75 
Previous Contraception 
Injectable 204(87%) 100(86%) 104(88% ) P=0.66 
Pill 20(8.5% ) 10(8.2%) 10(8.2% ) P=0.97 
IUD 0 0 0 
Condom use 164 (70%) 78(67%) 86(72% ) P=0.35 
Pregnancy unplanned 181 (77%) 97 (83%) 84 (71 %) P=0.346 
Socio-economic status 
Employed 61(26%) 34(31 %) 27(22%) P=0.265 
Housework 73(31 %) 33(28%) 40(33%) P=0.37 
Student 37(15%) 21(18% ) 16(13%) P= 0.343 
Seeking work 63(26%) 28(24%) 35(29%) P= 0.341 
Min school leaving 178 (76%) 85(73% ) 93(78% ) P= 0.321 
grade 9/ standard 7. 
Degree or Diploma 16 (6.8%) 8(7%) 8 (7%) P= 0.971 
Married 49(20%) 21(18% ) 28(23%) P= 0.33 
Single 185 (79%) 95(81 %) 90(76%) P= 0.291 
*Flsher's exact two-tatled. ** Significant difference p< O.05(ANOVA TEST) 
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5.4.1 Demographic characteristics of study participants 
Medical and gynaecological history 
There were no statistical significant differences between groups for almost all 
variables as measured by the Chi square test and Fisher's exact test were 
appropriate. Only one variable (CD4 count), had a statistical significance 
difference p < 0.05. 
The median ages of participants were 27.5 for the total groups, 26 for the 
DMP A and 26, 5 IUD group. Thirty nine percent of participants were in the 
18-24 age group, followed by 25% in the 25-34 age group, 15% 30-34 and 19% 
35- 45. Almost all participants were black, Xhosa-speaking women, with 
only four coloured women included. 
Previous Contraception 
Eighty seven per cent (87%) of the total sample size had previously used 
injectable progestogen contraception and none in both groups have used IUD 
before. No statistical significance difference p< 0.05 on use of condom. 
Socio- economic status 
Only 26% of the total sample group was employed and 64% had no source 
of income and only 7% in each group had a degree or diploma, majority had 
only grade 9 / standard 7 minimum school leaving qualification (Table 3). 
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Fi!'ure 7 pre>-ents the ,\ge d i <tribu' ion of the ~tuu y partiei I'<mts. 
rigure 7 , Age dislrib" lion oj 51 ,uly participcm t5 
Age distribution of participants 
• 
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5.5 Primary outcome results 
5.5.1 EPDS and BDI-II continuous data: Depression results 
Table 4 presents the depression scores as measured by the EPDS. Data are 
expressed as median scores [Interquartile range]. 




Time n Median n Median p- value 
(IQR) (IQR) 
Baseline 116 9(3 to 21) 118 8(2 to 20) 0.2 
1Month 110 4(1 to 18) 117 2(0 to 21) 0.04* 
~ 1 month 110 -3 (-7 to 0.5) 117 -4 (-8.5to 0.5) 0.3 
- ------- --- -
three months 113 2 (0.5 to 19) 117 2(0 to 19) 0.1 
~ 3 month 113 -4.5(-7.5 to 11) 117 -4(-6.5 to 16) 0.4 
P <0.05 (Wilcoxon test) 
There was no statistically significant difference between groups at baseline 
and at three months after randomisation, nor was there a significant change 
from baseline at one or three months. However, the median depression score 
in the DMPA group was significantly higher than in the IUD group at the 
one month follow-up. 
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Table 5 presents the depression scores as measured by BOI-II. Data expressed 
as median [Interquartile range]. 
Table 5: BDI median and scores change over time by groups 
BOI-II 
OMPA IUD 
Time N Median n Median p-
(IQR) (IQR) value 
Baseline 116 6(2.5 to 12.5) 118 5 (2.5 to 9.0) 0.1 
------
1 month 111 8(4.5 to 19.5) 117 7(4 to 12.5) 0.2 
~1 month 111 2(-1.5 to 8.0) 117 1(-1.5 to 5.5 ) 0.2 
Three 113 9 (4.5 to 14.5) 117 5 (2 to 11.5) 0.002* 
months 
~3 month 113 1(-1.5 to 6.5) 117 O( -3.5 to 4.5) 0.09 
*P< 0.05 (Wilcoxon test) 
There were no statistically significant differences between the groups in 
median BOI-II results for depression at baseline and one month postpartum, 
either as absolute values or changes from baseline (Table 5). However, at 
three months the median score for the OMPA group was statistically 
significantly higher than the IUD group (P = 0.002). 
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H.lseline c\' legoTlcal data for thp risk uf d~pre.,.o;:i()n i, pr<:'Sl.'nted in Fi~ure 8 
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StatistICal methuds IIS<'d fI'crr I/w Mmrtel-f-Iaenzrl mu,lyscs model, fixed cjfed 
mc~sure ,s tJ,,· nsJ. ratio uril" 95%Confidrnu ",t~n'al. 
111<.'r(' w~n' nil diff<'T~nccs in b~".,lin., depression rat .. " bdwL-ert the gruups 
with resp<'ct to mild In severe depr~ssion (Risk Ratio of 1.15 and 95% ('J 0.89, 
1.48) usmg the Ei'DS. Sinul.lr results were obS€n'ed for depression rates 
according tu BDI-ll scures. Twu DMPA group participants had hi~h scores 
falling in lhe category of major depressi"n (801., 29).Thes.e participants met 
tm- ",xdu~ion cril~ria for tm- study, howewr, due to a protocol vio lation. 
were includ",d. This prutocu] viulation WdS only noticed by the researcher at 




Ri~k of (kl'r,,~~ion at the on" month foll"w -up i ~ pre~"nted in Fi~ur" 9 for all 
u"pr"s~i"n thre~h"lu~ accNuing 10 EPlh and BOI"IL Data ar" "xpres!.Cd as 
risk r alius and 95~; confid"nc" int~'1'v also 
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nlfOSUrl' exprl's""d "s jll<' rISk m!:to with 95%Conjidm((' mlen,,,1. 
At une-munth there ''''\S a trend towards a greater risk of depn-ssion in the 
DMPA group ,ompared with lh€ IUD group, however, the 95% confidence 
interval does not cr06S 1 indicating that this trend wa~ not s"'ti~tical1y 
significant. 
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The ri<k "I depr'-'S~lon ilt thrw months IS prf'senled in Figure 111 ~"ording to 




a'[,s .. tl " '" " '" 09J rJ 3'O,211) 80< "I ' • '" " '" , 1~ rJ S • . 211J ~ so< ~ J(J '" m " '" I n rJ 89, J :Ii' 
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sO< '" ]! " '" 
, ." ·· ·rJg(l.ISO~: , , , , , , 
" "' a , 
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" , '~,[~,,, . ,~, ,,,,, IUD 
51,,1;81Icl1l me/hOlds 1(,""" Ih" Ma rr /d-llaenzel arralyses mood, fi xerl effect "'<'awn 
expresf'i'li I1R tiw risk rJlw wllh 95%CD>lfidmce irrten'ai, 
At 1m"", months follow-up, tr..,re W~~ no ~tntistkaHy ~Ignilkant dilfcrL'Il<"e 
bt'twt'en rates of depression in the DMPA and IUD groups lor either 
derr,-'Ssion scales. However, w11h the I:IDI-IJ there WdS II non-significant trend 
towards more depression in the D?l..IP A group, 
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s . .'> ..> FPOS clnJ 1>01-11 cat~gorical dclta ' DL'pTe~~lOn r ... ~ul t, 
S . .'> .'.) rPDS smr,' results fur mild deprl'ssw" 
Figur~ 11 preS<"nls del'ression rdles of mild to S<""ere depress ion events 
(EI'DS s<:ores of;:, 4, between DMJ'A clf,,-j IUD groups. j)~l" is ... xpressed;lS 
pf'rcenlages 
tixure ', I : EPDS result" for prl'Va/<'nce of mild del're~sjo" 
EPDS SCORE?: 9 
W' 
3A5fliNE 
• D"" PA 
. IUI> 
Th ... r ... w ... r ... no ~tati5tically 5;gn;fi,cant diffen'nC"'5 b<.'tw ...... n the group' in the 
rate~ of mild to severe d.,pre~~jon accorJing to EPOS ,core, ill baseline 
1'=O.36{Yat<"S corrected Chl-square test), one month (l' =1129) (Yates corrected 
Chi-squat ... t ... st) and thT"'" months P = Oh] (Y~t"'5 corr ... ct ... d Chi-square , ... st). 
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5.5.3.2 
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.~""'" lMON1~ 3MONT~S 
Thcr~ was nu statistically significant diff~rencc in the rate uf ""veN 
depression betw""n the groups at baseline p= P,41 (Yates mrre,ted Chl-
s'luan> test}, One munth P- 0.55 (Yah" corrected Chi-square test}, am! thr~e 
months p- 0.93 {Yak'S cOfr< .. 'Cted Chi-square test}. 
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55.3.3 BDI SCo r,. resun , mild - St.·v a e 
Figure 1) presents d epress ion ra"'~ of mild to severe depre~~ion ('vents (1101 
score, of <: 14) be tween the DMI'A and IUD groups. Dat.. .. Me ('xpressed as 
""i.~jre 1J ; BDI rt!sU Its jM prel'U lenre oj mild-s,.vcr~d d'"l,ression , 
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11wre was nO st~tislk~lIy significant diffen"lCe in the prevalence of mild to 
""veTe depression lx-tw~..:n the f,'TOUp~ at baseline r K ().44(Yates corrected 
Chi-square test), one month P = O.25(Yates correc ted Chi-S<.j1.l'Ire I"sl) and 
three months P ~ ().13 (Yates currt"cled Chi-squart' legt). 
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5.5.3.4 BLJ I s."nre results moo'7ale - ,;ro,7f 
(Hll! scores of;:, 2(1) betw~'€n DMI'A and IUD groups. Data are expr"soed ".~ 
percenLlges. 
~---:---
Figllrr 1·1 : Rill rfSHlts for 1''''7JtdCllCf of mo.frra t,. - seven· drpn·ss;ou , . -~' ." . -------
BDI score:?: 20 
'" 
lMONT~ lMONTkS 
There was no ~t,1ti5tiCally signiikant difference in the rate of moderate to 
Chi-square test). one month P * O.29(Yates corrected ChI-square t .. -st} and 




Fi;;ure 15 present~ rntes of ~~vere depression events (IlDI scores of 2: 29) 
Figur" IS: HDI r"sult .• for I"n'aiellce ofsfvne depression , - • 
BDI SCORE ~ 29 
o DMrA 
l MONnt JMONTH' 
There WdS nu statistically significant difference in the prevalence of moderat~ 
to severe d~pression between the groups at baselrne P-O.24(Fisher eXdcl two-
tailed test), one munth P - 0.39(Y3teS CUITectt' d Chi-~quar~ t~~t) .At three 
months the incre,1s.e in ".,Vere d.,pression in the DMPA ~;ruup Wil" of 
(8/119 women m th~ DMPA group ilnJ 2/123 women in th~ lUD group). 
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5.5.4 ASEX continuous data: Sexual functioning results 
Sexual functioning scores as measured by AS EX are presented in Table 6. 
Data are expressed as mean ± standard deviation. 
Table 6: ASEX mean score results and changes over time 
ASEX 
DMPA IUD 
Time n Mean n Mean p- Mean 95% CI 
{SD) _LSD} value diff 
Baseline 116 9.5 (3.1) 118 9.5(3.1) 0.9 0.00 -0,82 to 
0.82 
One 110 12.9(4.2) 117 12.4(4.5) 0.4 0.48 -0.67 to 
Month 1.63 
~ One 110 3.4(5.4) 117 3.1(5.3) 0.2 0.8 -0.63 to 
Month 2.26 
Three 113 13.9(5.1) 117 13.5(4.3) 0.5 0.38 -0.86 to 
months 1.62 
~Three 113 4.2(6.4) 117 3.8(5.1 ) 0.7 0.37 -1.14 to 
Months 1.90 
-
There was no statistical significant difference in ASEX scores between 
groups, either in absolute scores or changes from baseline. 
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ASfX catf'goric,,1 d"I."; Risk of ~xual dysflfficlion n's\lh~ 
B,,~hnc cal,,!,;orkal d.lla lIlT ri4, of sexual dysfunction betwpen the groups IS 
pTe",,,..,ted in Figure 14 for ASFX thn"I,,,kls of "ach itf'm SCOTp 2. 5 "nd for 
101,,1 ,",or" <: 19 according i\SEX_ D"tcl Me E'Xpressed as ri~k r~tios and 95% 
,.,mfid"n~e intervals. 
r;gur~ 14: Basdin .. ';OntlJarison of DMPA &IUD ASEX items ami totul 
events "f tW sexual i"tercouT~'~';;:~~;:;:~~~~;::::::::::~~l 
"""' ~ 01«,"""00 ~, 
_,,.,, 0-;...", ... ~~ , 
0.0' "" """u;''''-'' \ , 
s, .. ""' O" o.." .. I~ 5 , " ... """ 50, E,o.",,, .'; , '" ",,, h_ '""',""""" " ". 
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o. m 
~ 
~ _ .1....-_ _ _ 
Stah sn..'tll methods used were Ihe M"l!td-H~mzd anll/ySl'S rllood, jixcd "fftd 
measu re is thf risk ratio with 9S % COllfiden" mtaval. 
There ,,"as no statistically significant difference In the risk of ,",,'xual 
dysfunction noted at baselin"_ However there was a tn'nd for morp 
particip"nts in the DMj'i\ group not lliIving intercourse within th" w"",k 
before L'flTolmenl lJ1 the study. 
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5,5,1) ASEX categoric,l] data; Risk of Sexual dysfunction r,,~ ults 
On~ month cakgorical d,lta for risk of s~xual dysfunction [x,tw""" th~ 
groups is pn'Wnt~d in Figur~ 16 for ASEX thresholds of .,neh ,t~m senr" ;:" 5 
and for tola] S('ore;:' 19 according ASEX , Data are express.>d as ri~k ralio~ and 
95 ')"0 c(lnfidence inh~J"\· JJs. 
rigllrcl6: Olio' 1II01llh wllll'ari~I)H of lJMPA ('J' lun ;\S1-:X itell1~ and tlJta/ 
eve/lts of nl) ~fX11i11 intf rCourSf 
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S ll1tistiml met/Mis i<s<'d {perl' :hl' Mm,ld-Haenzrl a""(~5fs "wi/ri. fi xrd efrer l 
",cil~~ r" is the l1:sk mho w, I" 95 % Omfidence II1trru~1 
rhere wa' no statistically significant diff~rence in ASEX scores, However, 
si},'TlificantIy mOTe women in the DMPA group had not resumed intercourse 
at one month postpartum. The Yat"s correct"d Chi-o,quare gave us p~ll. OO 
(P<O.05) showing the difference WdS statistically significant. 
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ThTL'" month c~wt:uric~1 d~t<I for risk "f sexU<I1 dysfunction h('lwt"'n the 
gH'UpS is PTL'Sf'lltL'l.1 in FIgure 17 fm ASEX thres holds of each item s("OT!' 2 S 
<Im] for total <;cure 2 19 acc ordin!, ASEX Oat" are expn'ssed <IS risk ",ti,,, Jnd 
Pi"",, 17: Thre,> month rotn}mrisu" vf DMPA & IUD ASEX items and events 
'-~ 
''',OJ, ,, Dr,' ''''''''' ~ < .. n ,n , la " .%_l~ "(."-,_.,, ..... • '" n '" ''' '' ''''.''''1 ... "'O<~ r>t''''"''~ n~' " '" n '" ' O<l r. ,,_ "III ... ' .... 8' . ....... , ,' . " 'n " '" , ,, ~ ·g. ll 'l 
S I"lislicai 'n.,t/rod" mere tilt MIlHld-F-lu"tJu l utJuITJ,-e5 ",atkl, fix ed ''fled measure 
lllere wa~ a statistically non-significant trend to more sexual dysfunction 
with OMPA in 1m, fir~t four categories. 
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,',:, ,~1 AS EX Item /; 5.:_f drive 
Figure "18 presents ASE~ ll<'m 1 sn:>rl>~ lor <;ex driw dyslun,tion,<, 5 
(represenling very weak I" no ~l'X dnve}, between DMPA and ICD groups 
D~la .tr" L'Xpressed as pen .... nt~ges. 
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Al baseline, 11% of 115 women in DMI'A group had a ""on,;:" 5 for ""X drive, 
and 10~~ of llR women in IUD group had the same. At one month follow-up, 
this propurtion increased to 46% 01 110 women in DMPA group. ,md to 35% 
increase from of 117 women in Ill<' IUD group. At Ihr<-'<' months, this 
proportion decreaS<.'5 compared to one month follow-up: 3R% of 110 women 
in DMI'A group and 26", of 117 women on Ihe IUD group s,coring ~ S bul 
remained non-significantly higher in th~ DMP A group. 
J"j7 
".".6.2 ASEX linn 2; Arousal 
Figurp 1 Q prpSl'nl~ ASFX itpm 2 ,;c'Jr'-'~ for An>l1~aj eo: 5 (5 represent lJ1g low 
amu""I), "'-'tw~'-'n DMP A il nd IUD Kfoups, Data are expressed as percentage 
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rix"re 19: Cmnpuri.",,, uf DMrA &fUD SruliP l'Vl'uts OfVl'ry difficult to 110 
Sl'X "rol<sal 
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At ba&plin ~, 7% of 116 wompn in DMPA group and 9% of 118 WOffiPn in IUD 
group had a score ;:' " for ,lfousai, This proportion increased elt one month 
follow-up for both KrouPS, to 39% in DMPA group (total 110 WDmPl') and to 
4'1 % in the IUD group (total J 17 women), The was not much of a diffcrencc 
l'N"twp~n th~ proportion at one month as (ompar<,d with three months for thc 
DMPA POU}'. How,-,,'cr th<,r'-' was a ~tatistically signifkant diff~r<'n(~ in the 
IUD !';roup in the onc m,mth and thrc,-, months rdt,-,s of "'-'xual arous.ll 
dysfunction P =0,05 (Yates corrt.>(ted Chi"s<]uare test). 
--~~------
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SS6.J ASEX firm 3: Vaginal ilJC/>W SS 
Figure 211 ptc-cnts ASEX item 3 {or v<\f,rirkll lu bric,ltion o.coreS 2:5 
(TI'ptescnling "very difficult vaf'inal luL,tication" 10 "never e xperiencing 
percent",;es. 
Figur~ 2Q: Cmnl",rison of DMPA & IUD event5 af women with difficult 
vaginal lubrication to dry vag;'", 
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t;l<';HlNl ''''O N I ~ 
At baseline, 8'\(. of 114 women in DMPA group ,md 9~, of 118 WOmen in IUD 
group had" score 2: _; on the vaginal lubrication item. An increaS€ in this 
prop<lrtion relative tn baseline was bein,; ob,enled, similarly to the arous,, ] 
SCOreS. In the DMPA group, 39 "1. of 110 women, compared with 33~~ of 117 
WOmen In the JUD group, had " o.corc :2: 5 on Ihe va,;inal lubrication. Some 
decrease in proport ions at thrL.., months re]ali,-e to onc month follow-up was 
seen: 33% of 113 1,'Ornen in DMPA group and 30% of 117 wOmen in leD 
group had a scme ~(i None of thL'Se differences WJS statistically signifkanl. 
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p<lrti~ip~nt~ wh" had h~J sexu~l intercuurse within ~ week of thE' iotE'rviE'w 
ThE'reiorf', th" numocrs PT"",ntcd in th", fulluwi,,~ chart only include thoS(' 
5.5.6.4 
Fil'lIre 21 pr,>S('nts a (omp~m;on of th" DMI'A ~nJ IUD gruup~ with .<;cOre' <: 
" on orgasm dvsfun<ti"" (very J,tficult to reach orgasm to neVer reaching it) . 
Figure 2/; Comparison ~(DArPA & IUD gn'"p <'vmts "I tllllim/ty to reach 
orga .• m to "" prgasm 
Orgasm 
lM oot ~ 
At b~S<'line. onlv 25% Df 12 participants in DMrA group and 16% of 12 
paTlicip~nt' in IUD puup have thi s ""ore Alone month follow-up 2.'\ % of 17 
WOmen in D\-lPA group and 15% of 26 PMti'--;pants in IUD group reported 
this SCure un orgasm. At the lhn,,-, munth folluw·up, 24% of 45 participants in 
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D~lI'lI and II ');, of t>.~ p.1ft i .. ir~n ts in IUD grnup rcrort('u hdvinf\" Jifficu l til~ 
SCOrel' for e~ch group nver timt'_ 
5.5, ~ 5 ASEX 
Fif,'Ure 12 pn-'N-'llts IISEX item 5 SC(lf~o;; for sati sf,lcti(ln ~ 5(repye;;enti"g ~'el}' 
uru;at i:;fying e~periellCe among the women wh" could not re~ch orgasm) , 
betW""1l DMPA and IUD ",roups. D~ta an' "xprC55nl as pcrcelltdf\"~<;. 
FigUrl' 22: Compatison of DMP!I & IUD groul' JM ",mils oj UJomm 
nperiencing ,,,,salis/ying orsasm or can't reach orgasm . - - - -












BASHJNE 1 "ONT~ 
At basdine, there wne IlO p~nicip~nl~ in both grnup~ who had scores 2: 5 for 
<;e xua l 5.1tisfaction. At one month follow-up, 18"0 of 17 partkipants on th" 
DMPA gruup h<!d »cort's ~ 5 indicating Ie;s satisfaction with their orgasm, 
compared with15·~ of 26 participants in IUD group_ At thr('(' month follow -
up, ! fl ', uf 45 particiranh in DI>II'A group and 5% from of 63 pdrticipants ill 
IUD group Wne also less Sdtisfied with the expt'rience. 
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A SF X t,,/al ,' n".c ~ 19 
Figurt' 23 pr<'S€nts .A.SEX lolai scores ;:>: l'l(r~prC~I'nts St')(u~l dysfuncliDn), 
l-'igurp 2J: COfIl!",ris ,m nf n"'PA & nm gro ups fur ~v .. "fs "f SHII"I 
~fJ5fllnr!!~"'~' __ ____ _ 
Asex tota I O?: 19 
,,, 
' ... "NI'H 
At b~seline, e;)Ch group fkld only one study p,lrticipant wi th " lobl scores ~ 
19. Alone monlh, 4 .. ~ ~o of 110 parlicipanls in DMl'A group and 2.5% of 117 
participants in IUD g!'0up reportt'u St,xual dysfunction. At three months, this 
proportion increased to 11 % oj 113 partlCipants in DMPA grou p and 10% of 
117 participant. in lun gmup. These diff~rences were nol slatistiG.lly 
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5.5.6] 
Figur(' 2.t presents th~ rate "~I return of ",xuai int<'n'st, 1>l-'lwO'O'n f)il.1PA ilnd 
IUD group~. Data are expreSS€d a, perccntag"' _ 
Fix",-e 14: Comparison of DMPA [y Iun group's rdunr "f"~-~ iI/ten'S/ , - --- --- -~-~. 







BI>S[t11;E IMO"T~ J"O~T~S 
o OMPA . ,UD 
In addition to the ASEX. a qu~stion wa, asked at all ~tudy time poinl> 
(baseline, one month and thn'" months) whether study participants have had 
sexual inl<'rcourst' with in the past month. At bast'line there was no 
statistically significant di fference betwl't'n the study groups of participonl;. 
who did not hav" s"xual intercouf"'_ At on" month follow-up, mor" 
participants in the IUD f;J:oup(30 of 117 particip~nts) c(lmpared "ilh the 
DMP A group(14 of 111parlicipants) had engaged in s<'xuat intercour"",,; Ihis 
diff"r"nce lV~ s statistically significant r =0,02 (Yates corrected Chi-square 
test),At three months (64 of 115participants) IUD group hau mOfe 
p;;lrtici p~nts whl' had engaged in se.~ ual mtercoorse a~ cornpML"-l to the 
-'-L~' .. ---------
DMI'A group (53 of 111 partkirants);this diff" ... 'n".' was not stati stic"lIy 
signifkant 1'=0.29 (Yates COrrt'Cted rhi-S'luilr" t("; t) 
5.6 S"wnriary outfOl>lrs rrs,,!t.< 
5.6.1 M~nstru.lI Fluw 
Figur~ 25 presents the risk of menstrual disturbanc5 within the two f;T<>uPS. 
Oa t" are exprl'~<;ed as n~k ratios "nd 9,~ % cnnfidenc<' intervals. 
Figurr 25 ; Comparison of rJMP/\ &JUrJ group's metls lmal flow ,1/ ",tiC 
m.mlh p(;Jslparlum 
, , _.n . ., ,,,, .. ' !/I't ," 
_,,!tu ... ,,""' ....... , '" "" .... nw'''. "" r., '" 
." 
" '" , '" " '" 
, 
1 JO I07l. 1 i e, 
00< 10 n. J 0'>1 
09~ 1!l ".1 1 1t 
, 
Slllli ~ljml mctlwds used were Ille COChfitri Muntd-Ilamul unlll.'!",·" model, / iwd 
eifrd measu re is th~ risk mtio ph,,-ed lit 95% Confid"" c~ mtn-val. 
rherf' was no statistically significant diff'-Ten~e in risk for menstrual 
disturbilnces between the groups. 
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Figure 26 pn·sents the ri sk of menstrual disturbances between the two 
grrlUl'S ~t thnoc m(l11ths 1'0"tp.1rtum. DM" ~rE' expre,sed as ri sk r~ti os ,md 
95');, confidence mtervals. 
w,,,,.,,,, " 0," >0" 
' Io mon • ..,.",., '" '" t , 0" , 
- __ ' {OoO~ -_1<_>1 
There was n(1 stdtistic~l ~ignificant diff.mmcE' in thO;' risk of menstru.Jj 
d;sturh~nCL'5 hE'h"Locn thE' groups. However there W,\S ~ tr~'nd towards mOre 
particip.:mts in the DMPA Woup I",vin,; hedV}' m('ns!ru~tion comp~fl'd with 
thE' lUll group (RJ( < I means lhe eve,nl IS less likely to occur in the D:.1PA 
group). 
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Figur~ 27 pre~ents pre\'"knce of norm,,!, li~ht and heJvy menstruation, ,1S 
well ,I, omenorrhoea, betv..'L",n DMPA ,11ld lUll groops Data are exprf'Ssed 
F(~ur,'17: Comparison 0/ DMP:l [~ IUD grOllps 'menstrual flow 
~'AvnMO'\.-'''-; 
l'G~T lMO·\T><S 
"O kM .... ,3MONT>6 
"GN'.3M01'1TII 
~'AW,'MONT'" 
" G~T "M:) "'~ 
N0 ,VAI.:1MO·\T" 
\c NE, !MO·\TII 
Menstrual Flow 
There was no stJlistieal difference in menstrual flow at both follow up srudy 
points (one month and three months) for menstru,,[ flow between study 
pJctieipants, 
The prevaleoce of amenorrhea alone month was 59% for the wh.,le sdmple 
(131) out of 227 particip"nt"l. which decre"sed to 28% (M/225) Jt three 
months, 
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SAl M enstrual J'ain 
Figllr~ 28 rre&f'llts the n~k oJf d ysmenorrhea within the tW<l ~roups .tI one 
month postparl.um_ Data ar~ expressed ell' risk ratios ~nd 9S ':{. ( onfidence 
intervals_ 
E.ig!!.,e 28: Comparison vf DMPr\ [y IU1J group: dy_~men"rrhellilt 1 monti, 
~A IU(J ;o .. fIM<, ..... _ 
~~ ~-
~" ."" 
~"". " •• o.m 
S . .. " 0'" 
S tn/,,/iml nldlwds used were the CoeJmm Mantel-liaenzd illralyses modl'l, fiXfd 
-!fret ", . asu/'f' is the risk ratio placed a/ 95 %Confidence i."len'nl. 
There was n<l significant differenn' in the risk <If dysmen<lrrhea bdwl'<'n the 
firoups ~t OJle month p"~tp~rtum_ 
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Figure 29 pre~ents risk of menslrual p~in wIthin toe two group" al lhree 
mouth, p<"tpartum Oat" is expressed "s risk ratios ~nd 95% nmfidc nce 
intervals. 
Fi.~ur" 19; ComparisiJn of DMP.4. & IUD dyslUl'n(Jrrh"" "I 3"'<JlIl/J,--, 
~"'!I"~ h _ ,-
p .. .... " "' " ..,;., 0"0 " " role"." • ., o>on , " s .... ,. ... " , " 
-,- ,-
"' • " " , " , " 
.,,,,, ,,",,,, 
,., II. , --. .,,>-\<.1 
l 1T rJ !I8, l J'I 
o 71 11 .1', 1 ~11 
05l)O ", 11~ 
o~~ " Ii , , 6ll 
"" ........ " ". Ii,"" ."" u 
+ 
Statistical m,.ti":,,is u,;,>d Wl'rr III~ Cochran Mmlt~I- I'I,,"'rul m",ly:x'S m(Jdd, fiwd 
There was no slgnificant difference in the M,k of dysmenorrhea bet\."een the 
groups at three months postpartum. llowever, there is ,I trend for the LIst 
three <:ategori<.'s (mild, moderate and se"ere pain) to occur more ff<''-Juently in 
the IUD group compared with the II)MPA gTOUp (RR < I). 
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Figure :\0 present ' f"l!V,llenre of normal , light ,1nJ heavy menstru,ltinn as 
"ell as d ysmenorrheil bdwi'l' 1l DMPA and IUD group~_ Data ar" (,)(pre_,_",u 
,f iXJ1re 30: DysmmiJr"""',"" _____ _ 
PA M.{SS IMONT ~ 
Dysmenorrhea 
,-, --
Only wOllwn who had menstruation at the,e time points could answer 
whctht,r they had men~trual pain or not. For roth groups, the majority of 
wom"n had n,) menstrual p,linS and th('T<' was nO ~ih'T1ificdnt Jifference of 
dysmenorrhea among the two grouP"_ There is just .I slight trend nr mot(' 
ewnts in the IUD group rnf mild pain cump,u('d with the f)MPA group_ 
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5.6.3 \-Veight "h~ ll r;cs 
F(\iU rf 31 : Co mpurjs ,,,, of a lte~~d 
A weif';ht gain index (weight g.lin minus th" number reporting weight loss 
worry) captured bulh ~spects of ~hanges in weight (Th\1PA 2/38 VPTSUS IUD 
5/37), 
f'igure 32: Comparison of altned weight at J month , --
A weigh t gain index (w~ i ~ht gain min \l ~ th" number reporting w eight loss 
wurrv) tn capture bo:,th ~~p"cb of changes in weight Chil llg'''' W,b 
\l n d('rt ~ken . The Y,lleS corrcded Chi-S<J" an> test shuwed the'" Wa< a 
~t ati.,tiL'<l l s ignificant diff"rt,,--, ct' in the welght Ii"in indt:x (DMPA 11'1/40 
\' crs u ~ I Uil 5/45) ""' tween OM!' A ,md IUD, P =0.00 (P:> ll05) 
- ----------
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Figure 33 presenLs pn'valcn,:c of weight loss and weight gain b€twet'n 
DMI'A and Icn g-roup~. D~ta ar~ L'Xprc~,",-'{[ as percentages, 
i Weight chang~ 
-----; 
w{]G~' lQ!S, lMONI~ \ 
ThLs summary indudes those women who Nid they were worried aoout 
their wc>ghl There is no dilf~rcnc.., m thc preya{'£nn uf weight gcl;n and 
weight 10 .• s between DMPA and IUD' group'. Morr partiopants in the [ClMPA 
compl<lined of weight gain than the IUD group, howeycr, tr.i~ diffcrL'llCc wa." 
l\(]t st" Lishcally significant, 
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5.6.4 CJ;ol(es of feeding option~ 
Figures 34, 35, ~nd J.t, pre,;ent~ the risk {,f bre"stfeeding, form lila feed ing and 
mix f""din,; at baseline. (lroc month and three months. tb(a Jre ('xpre~",d as 
ri:sk mtios ~nd 95"1. confiden,e intervals. 
Figure 34: Campar'.'"'' of DMl'A &,IUD/eedi"g ""firms ,,/ base/i"" 
Ol"l'~ 111(' .... _ ...... ~"' • 
B""'''"''''''<j B..". ." "", . .. , 
",,, "odny " 
. _'-. f!I"oU 
," 
Slali~I",al mefilnds were II", Mtmtd-HQnI:d ~"ldyse5 modd; fixed effrd meaSure 
0IJrl:ssed ,IS tllc risk rat", lrith 95 % C,mfidellcP '"Ien'ni. 
There was nO stJtisticJ liv s i~ificant differc",-(> in the choice (If feedint, 
be\w('('n the twu gruup~ at baseline (Figure 34). one munth (Figure 35) and 
three months (FIgure 36). 
35 ; 
8.1,,",.,,,1. roo .. ~,. .""'~ 
5tatistimi me/hods werr the Milntcl-HMnzel anlll"ses mode!; fiwd ''ifect measure 
exprrs&'d a~ the nsk raJio wdh 95 % CooJ/idma mterllal. 
-16; lJi\IPA & IUD campuri~on ~~~~:;;;~~~~2~~===:: 
) , , 11 
Slut,,;t,,,,,1 melh(ll/s wae Ihe Mmtel -llmmzr! analyses moor!, fixed effect meaSHre 
expre~""d as th e risk mho wJlh 95%Cunfidellfe lIl/aval. 
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Figure 3i pre~en!s the rate, of fl'l'uing OptiOll" at bdselin~ L>l'twL'eIl DMI'A 
<lnu IUD />'T"up<" Data Me expresseu "s percentages. 
r;g"r~ .17: r cedillg op/iolls ,,/ blls,-' me 
-~~~-
Feeding options baseline 
. OMP~ 
fCRMlJlA MIX 'fIliNG 
At enrolment, women were ,Isked about dedsions they held already rrwde 
about their choice of feeding option_ At tt;., two participating ~tudy site", 
('xdusive bre~"tfeedillg is encouraged and women are supporte.1 to initiate 
brea,tfL'"ding whilst in hOSpitaL No Jifferd'oCL's wer" noted between the 
llMPA and lUll in their le",ding uptions at base!'ne. 
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Figure 38 pres..,nb the rates of feedll1 g "ptHlns at one n1(lnth p<'stpartum 
figure J& : f:ecding o"t;ons at on<, month -
Feeding options at Imonth 
.,. 
. OMPA 
"'X f E [~N G 
There wa, no signifjcant difference between the DMPA and IUD groups with 
regard to their feedmg choICE'S at on.,., month. Although th..,...., weIe more 
pdrticipants in the IUD gruup who mix fed than the DMPA group. this 
difference was not statistIcal sigruficant. 
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Feeding options 3Months 
B"["~H[EDI~ 
_ DMPA 
lllcre W<iS no signific~nt Jifferc'T1Ce 1,,'lwt'€n the PMI' A and IL;D groups with 
regard to their feeding optiuns a\ u~ munth. Although th."...., wen; more 
partkipants m tht: DMPA than the IUD group who formul" fed their babIes. 
~nJ more participants III the IUD ~roup whu mix fed than IIw DMPA group. 
these differ~nc", were not statistic" I si gnificant 
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5.7 Summary of Results 
Primary outcomes 
The study questions were to ascertain whether: 
• There is a statistical difference in the effect of injectable DMPA on 
depression as compared to the Cu-IUD 
• There is a statistical difference in the effect of injectable DMP A on 
sexual functioning as compared to the Cu-IUD. 
To answer the first question, two depression scales were used: the BDI-II and 
the EPDS. Depression was expressed as continuous (means/medians) and 
categorical variables (number of events) for each test and the relative risk of 
depression in each group was calculated to determine whether there was any 
difference between the groups. A 95% CI which spans from <1 to >1 
indicates no statistically significant difference between the groups at the 5% 
level. 
At baseline, group characteristics were similar and the incidence of 
depression was not significantly different between the two groups using the 
EPDS (mild or severe depression categories) or the BDI-II (mild-severe, 
moderate-severe and severe depression categories). 
Results at one month after randomisation showed a statistical significant 
difference between median EPDS scores in favour of the IUD (P=O.04). 
However, there was no statistically significant difference in median BDI-II 
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scores (P = 0.2) at the same time point. For the categorical data the relative 
risk of depression at one month for both the EPDS and BDI-IJ scales showed 
a trend towards more depression in the DMP A group for all depression 
categories, however, the incidence of depression was not significantly 
different between DMP A and IUD groups. 
At three months, the BDI-II showed a statistically significant difference in 
median depression scores in favour of the IUD group (P = 0.002).However, 
median EPDS scores were not statistically significantly different (P=O.l). The 
risk of depression at three months was not statistically Significantly different 
using either the EPDS or the BDI-II scale for any of the depression categories. 
ASEX was used to answer the second question on sexual functioning. As 
with depression, data for sexual functioning were analysed as continuous 
(mean ASEX scores) and categorical data (number with sexual dysfunction), 
and the risk ratios calculated. In addition, the resumption of sexual 
intercourse was evaluated and compared between the groups. 
At all study time-points, mean ASEX scores were not statistically 
significantly different for sexual dysfunction between the groups, either in 
absolute values or in change from baseline. There was no difference in the 
relative risk of sexual dysfunction when data from all 5-items of the ASEX 
(sex drive, arousal, vaginal lubrication, orgasm and satisfaction) were 
combined. The incidence of sexual dysfunction was not significantly 
different between the groups as well. However, significantly more women in 
137 
the DMP A group had not resumed intercourse at one month (P=O.02) 
compared with the IUD group. 
Secondary outcomes 
For all secondary outcomes incidence rates and relative risks were calculated. 
There was no significant difference in menstrual flow between the groups at 
one month and three months. There was a trend towards more menstrual 
pain (mild, moderate and severe pain) at three months in the IUD compared 
with the DMPA group. There was statistically significant difference between 
the groups with regard to complaints of weight gain at three months which 
were more common in the DMPA group. There were no statistically 
significant differences between the groups with regard to feeding options at 
any study time-point. 
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Chapter 6: Discussion 
6.1 Introduction 
The previous chapter presented the results of data analysis perfumed using 
Statistic a and Revman software. This chapter aims to put into context, 
discussing associated literature that aids to clarify why the results observed 
might have been anticipated and how this influence our understanding of 
the effect of DMP A and IUD on depression and sexual functioning. 
6.2 DMPA and IUD on depression 
The primary outcome on which the sample size calculation was based was 
the depression score. In general depression scores were higher in the DMP A 
group, but few analyses of difference between the groups reached statistical 
significance. Some results that were significant were not consistent across 
depression scales: For example at one month, the increase in depression 
according to the EPDS, but not the BDI, was statistically significant. At three 
months, the difference in BDI scores was statistically significant but not the 
EPDS scores. The results of the study, therefore, need to be interpreted with 
caution. Although the results are highly suggestive of higher depression 
scores with DMPA, this trial in isolation cannot be regarded as conclusive. 
However, this study is the second randomised clinical trial to evaluate the 
effect of injectable progestogen contraception on postpartum depression. In 
the previous study (Lawrie et aI, 1998b), also conducted in South Africa, the 
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pmgcst(lgcn ini''("t~hl,' contra<vption NET-EN was sta tiSlkal ly significantly 
.l"S(ld.1tcd with postp.1l'tum dq'r~ssion at six weeks PlJstp"rtum, comp"red 
with placebo (P '" D.lli12). This df~ct had 'worn off hy the thr"" rn(lnth 
.lSSf'5Smenl , possible bec"ust' WO!TIen in this study rl'ceiv~d only one 
in;,..,li(ln, and NET-EN h.ls " durJtion "r acl ion "r .1pprnximately IWO 
months. 
When Ihe resu lts from Lawri" et .\1 {l!J')8b} a re considered togethn with the 
r~"ults of this stu,i )" then' is smIle mmpdliIlg ('vidence that posIparlum 
injectJhle progestogen rontrJ(eption is .lssociate.i with increased d~pl'L'"sion . 
s.,,, the p(l(lled r~sults in ,''' ploralory meta -~nalys('s bel"w: 
'''' .. , ..... ''' , " n., .... 
l<Ut .... ,,, " ..... '_""., ltv" • • 00, C ... . O. lI, ",. , tp. "" .• •. 0% 
,.,,"" .-.-."., ... " Z . 1"" IP, 0 000) 
'"".U.l,''' 
fit 4 to 6 weeks 
, ...... ,·.c, 
'''~'''-., ,,, " '001 ,', -i ,~ H .... .., •• " .,- l • .,.. 0."'. Chi'. 0 or, .. . , " . '.ft) •• • " 
T." '" ,,,.,, .. ... " l. , '0 ¥'. 0 "') f._. """"""" h, ... , ,,,,,~ 
", ~""'8 ""' •• " '" ~ ... , 
m ""'·11 '<ON' ." .r. " ... . 
Thes~ pOlJkd n$ults are limit('d because th E'Se studies differ in the type of 
progeslogens used, the duration of contraceptive action of the proges t"gens 
{DMI'A j" sts three m(lnths and NET-EN h'sts 2 monlhs}, the different 
140 
depression scales used, and the time-point for follow-up assessed (four 
weeks and six weeks, respectively). 
The only other study of DMP A and postpartum depression is previous 
retrospective study (Tsai & Schaffir, 2010) that showed no statistically 
significant difference in depression with DMP A users as compared with non-
users in the postpartum period. 
However, the quality of the evidence from the current study and the study 
by Lawrie et al is much higher due to the use of a randomized controlled 
study design. This study design eliminates selection bias (Schulz & Grimes, 
2002).In addition, detection bias was reduced in both randomised studies by 
blinding the assessor. 
The two depression scales (BDI-II & EPDS) did not give equally significant 
results at the same time points (thought the trends were consistent), and this 
can be expected as these two scales measure different aspects of depression. 
The BDI-II includes questions about somatic disturbances as opposed to 
EPDS, and is used to measure the severity of depression rather than to 
identify depression symptoms as does the EPDS (Curzik & Begic, 2012). 
The incidence of severe depression in Lawrie et al (1998) was approximately 
10% (16/162 women) at the six week assessment, measured by the 
Mongomery-Asberg Depression Rating Scale (MADRS). In this study, the 
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incidence of severe depression was 8% overall (18/228) in women assessed at 
four weeks 
6.3 DMPA and IUD effects 011 sexual functioning 
These study findings were inconclusive as to whether participants receiving 
DMPA after delivery have greater risk than those who received the IUD of 
sexual dysfunction in the postpartum period. Evidence from previous 
studies is conflicting. Galbaci & Terzioglu (2010) found no significant 
difference in sexual functioning between hormonal and non-hormonal 
contraception users. These results were endorsed by Schaffir, Isley and 
Woodward (2010b), Davis et al (2005) who found that even low androgen 
levels in hormonal contraceptive users did not introduce negative effects on 
sexual functioning. However Sabatini & Cagiano (2006) found a negative 
effect of COCs on vaginal lubrication influencing sexual desire dysfunction. 
Results of other studies (Kaunitz, 2009; Matson, Henderson & McGrath, 1997; 
Paul, Skegg & Williams, 1997; Berga & Smith (2012) suggest that DMP A 
interferes with sexual interest and breastfeeding with negative effects on sex. 
Our study did not confirm these findings. However, the methodology of 
these other studies is limited: most are observational studies; one, (Kaunitz, 
2009), randomly allocated participants to intramuscular DMP A or 
subcutaneous DMPA, therefore this did not have a non-hormonal control 
group. 
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Several studies have found negative effects of assisted vaginal delivery 
compared with caesarean section on sexual functioning, (Safarinejad, Kolahi 
& Hossein , 2009; Basku 2007; Hicks et al 2004).However, the opportunity to 
record these data in this study was inadvertently missed. 
The results of this study regarding sexual function should be treated with 
caution because factors affecting sexual function in the postpartum period 
are complex, including perineal pain , method of delivery (vaginal or 
caesarean) and adjustment to motherhood, which may override more subtle 
feelings regarding sexual function. The ASEX questionnaire may therefore 
not have been sufficiently sensitive to detect differences in feelings between 
the groups. However the one 'hard' outcome measured, whether or not 
sexual intercourse was resumed within the first month postpartum, was 
statistically significantly difference:, More participants in the IUD group, 
had sexual intercourse within the 1st month compared with the DMPA 
group(25% vs. 12 % ,respectively; P= 0.02. This outcome may be a more 
robust indication of sexual function in the context of the postpartum period, 
than the more subtle questions which make up the ASEX questionnaire. The 
25% recorded in the IUD group is similar to the proportion of women who 
had a return of sexual interest in a Nigerian study which reported a rate of 
sexual intercourse at six weeks postpartum of s 29.7% (Ezebialu & Eke, 
2012)". By contrast, in a Canadian study, a high percentage of postpartum 
women (47%) had resumed sexual intercourse at 6 weeks (Rowland et aI., 
143 
2005).In the latter study, breastfeeding was reportedly associated with the 
delay in the resumption of sexual intercourse. 
Current practice of clinician in the two research sites is education of women 
not to resume intercourse until six weeks postpartum; in this study their lack 
of sexual activity at six weeks postpartum may not be all significant. 
6.4 DMPA and IUD effects on menstntal disturbances. 
There was a significant difference in the menstrual flow index between the 
groups in this study, with cu-IUD group having a greater risk of heavy 
menstruation than the DMPA group. Therefore this study adds to the 
existing evidence that IUD users experience heavier menstrual flow than 
DMPA users and non-users (Grimes et al., 2006; Zhou& Xiao, 2001). DMPA is 
known to cause menstrual irregularities; however, it is likely that the three 
months duration of this study was too short to demonstrate this effect among 
users. In women who discontinue injectable progestogen contraception due 
to menstrual irregularities, the cu-IUD may be offered as alternative 
(Adeyemi & Adekanle, 2012; Hajikazemi, Nikpour & Haghani, 2004; Wood 
&Jewkes, 2006). 
Significant difference in the rate of amenorrhea menstruation would have 
been expected under normal circumstances in these two groups, as 
amenorrhea is more common with DMPA use (Draper et aI, 2007, Hubacher 
et al, 2008) as discussed in Chapter two. Again, it is likely that the three 
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months duration of this study was too short to demonstrate differences 
between the groups with regard to amenorrhea as this effect tends to occur 
with duration of use greater than one year. 
6.5 DMP A and IUD effect on weight changes 
This study has showed that DMP A users are more likely to experience 
weight gain than cu- IUD users. The weight index of the DMPA group was 
statistically significantly difference from the IUD group, (P =0.00) These 
findings are in agreement with the previous studies that have reported 
weight gain as one of the disadvantages or complaints from DMP A users 
(Haider & Darney, 2007; Nyirati, Habash & Shaffer, 2013; Vickery et al., 2013; 
Westhoff et al., 2007b). Furthermore these findings of weight changes with 
DMPA use add to evidence that was shown in a South African study as well 
(Beksinska et al., 2010). This effect on weight may be particularly undesirable 
in the postpartum period when women are eager to get back to their pre-
pregnancy weight and, arguably, might adversely affect mood. 
6.6 DMPA and IUD effects on feeding options 
This study did not show any difference in the rate of different feeding 
options between the two groups. However, a decline over time in the 
prevalence of exclusively breastfeeding is observed with an increase in either 
formula feeding of mix feeding. The reason for including this secondary 
outcome was to establish if there is an effect of hormonal contraception on 
milk quantity and mother -infant bonding. 
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In this study assessment of milk volume was done by assessing the need for 
supplemental infant feeds, and there was no difference in the two groups. 
This finding is in agreement with previous studies that could not establish 
effects of hormonal contraception on milk quantity (Espey et al., 2012; King, 
2007; Truitt et al., 2009). 
The second intention was to assess mother and child bonding as 
demonstrated by breastfeeding. The extent of mother and child bonding was 
intended to evaluate if postpartum depression had a negative effect on 
mother and child relationship. However, unlike the study of Cooper et al 
(2009), that reported major depression to have negative effects on mother-
infant bonding, this found no association between type of contraception and 
mother-infant bonding. 
6.8 Strengths of current study 
The main strength of this study is the use of random allocation to the 
treatment groups with allocation concealment. Random aIlocation greatly 
reduces the risk of spurious results due to confounding factors which may 
occur with any non-randomized methodology. 
Other strengths are the high follow-up rate, and the use of intention to treat 
analysis. The latter means that effects attributed to the interventions are 
unlikely to have been over-estimated. 
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6.9 Weaknesses of current study 
There are several weaknesses in this study. The first was that the study was 
powered to detect differences in mean depression scores; it was not powered 
to detect differences in the categorical depression outcomes nor the other 
secondary outcomes. It is therefore possible that the study failed to 
demonstrate important differences in these outcomes (type 2 error). 
The second weakness was non-compliance. Six women in the IUD group 
received DMP A. This deviation from the protocol would cause systematic 
under-estimation of any differences in outcome between the groups. A per 
protocol analysis would reduce this underestimation, but would lose the 
benefit of randomisation and introduce the possibility of bias which would 
be unpredictable both in direction and size. For this reason, the analysis has 
been limited to the more conservative 'intention to treat' analysis, 
acknowledging the potential for under-estimation of effects. 
The third limitation is the duration of follow-up which was short and certain 
outcomes such as menstrual flow, and sexual dysfunction were not easily 
assessed as participating women were still in the postpartum period. 
Another limitation was the inconsistency in methods of data collection. The 
majority of women were interviewed telephonically as per protocol; 
however, for those who could not be reached by phone, home visits were 
undertaken. The data collection forms where completed by a trained 
fieldworker during these interviews. 
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Self-reported screening tools (EPDS and BDI-II) were used to measure the 
primary outcomes, no clinical diagnosis was made. 
There was no measure for confounding factors that may be associated with 
the risk of depression, such as unemployment and relationship conflicts; 
however, randomisation should have ensured that these unknown factors 
were evenly distributed between the study groups. 
Only women who came from Amatole district of the Eastern Cape took part 
in this study. As participants only received one injection and were followed 
up for only three months, it is possible that these results may not be 
applicable to women who have been using these contraception methods for a 
longer duration. Also, women in this study were recruited postnatal; 
therefore these results may not be applicable to women at other times of their 
reproductive lives, e.g. adolescents or women without young babies. 
6.10 Conclusion 
Statistically significant differences in depression scores and rates of 
depression between women allocated to DMPA or the cu-IUD were limited 
to one continuous measure each at one and three months on different 
depression scales. 
No statistically significant differences in sexual functioning between the 
study groups were found, however, women in the IUD group were more 
likely to have resumed sexual intercourse by three months postpartum, 
compared with the DMPA group. Therefore, the results for this study are 
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inconclusive with respect to the primary outcomes and we are unable to 
robustly reject the null hypotheses. 
Although, the trend towards more depression in the progestogen group 
needs to be interpreted with caution, previous robust research on NET-EN 
(Lawrie et aI, 1998), this study contributes to the body of evidence suggesting 
that long-acting progestogen contraception probably increases the risk of 
postpartum depression. As only one progestogen injection was administered 
to women in these studies, it is not clear whether this effect is likely to be 
transient. 
Postpartum women are particularly vulnerable to depression; therefore these 
results may not be generalizable to women at other times of their 
reproductive lives. However, it is important to bear these potential effects on 
mood in mind when offering contraception to postpartum women and 
women who may depressed, or at risk of depression, until more evidence 
becomes available. 
6.11 Implications of this study 
• Family planning providers should inform women during 
contraceptive counselling that there is no certainty but a possibility 
that DMPA injections may cause depression and/ or sexual 
dysfunction. This implies that enough time must be allocated by 
149 
provider for method counselling during antenatal care when for 
choosing a suitable contraceptive method. 
• Using DMP A immediately after delivery may be associated with less 
than desired postpartum weight loss than non-hormonal methods. 
• Women using injectable progestogens should be screened for 
depression at their six week follow-up visit and, if found to be at risk 
of depression, an additional follow-up visit's should be scheduled, 
with appropriate referral if indicated. 
• The IUD is a useful alternative contraceptive method for DMP A 
contraceptive users who cannot tolerate side effects if they occur. 
DMP A users can continue to use DMP A with confidence as a 
convenient and effective method of preventing unintended 
pregnancy. 
• Policy makers and governments can promote the use of long acting 
contraceptive methods with the knowledge that the risk of side effects 
outweighs the burden of unintended pregnancies. 
6.12 Implication for research 
The findings of the study raise sufficient concerns to justify further research 
with larger sample size and adequate power to answer several of the 
supplemental aims. Such a randomised controlled trial should ideally be a 
multicentre trial conducted over a longer period of time. 
150 
A large sample would be able to clarify whether the trend to more 
depression found with injectable progestogen is significant. In addition, it 
might enable greater understanding of the course of depressive symptoms in 
postnatal women using injectable progestogen contraceptives, and whether 
depressive symptoms in these women are sustained or transient. 
Further research is needed to determine which groups of women, if any, are 
more vulnerable to becoming depressed on long-acting progestogen 
contraceptives, in the postnatal period or at other times. 
A Cochrane systematic review and meta-analysis of available high-quality 
data for long-acting progestogen contraception compared to the IUDs 
methods should be conducted to provide women with the best possible 
information regarding relative benefits and risks of these two important 
reversible methods of contraception. 
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APPENDICES 
Appendix A: (English) Information and consent fonn 
UNIVERSITY OF CAPE TOWN 
School of Health & Rehabilitation Sciences 
Faculty of Health Sciences 
Name of Researcher 
Name of Organization 
Name of Sponsor 
Department of Health 
Name of Proposal 
Mandisa Singata 
University of Cape Town 
Effective Care Research Unit, Eastern Cape 
"A randomised control trial studying effects of 
Intrauterine-device and Injectable Progestogen contraceptive on depression 
and sexual functioning of child-bearing women in the Eastern Cape 
Version and date: July 2012 
Ethics approval number: FHS HREC: ref number 548/2012 
This informed consent form has two parts. The first part is an information 
sheet containing brief outline of the study. The second is a certificate of 
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consent that you are required to sign indicating your willingness to take part 
in the study. 
Part 1 Information sheet 
To be read by or to each prospective participant in her language of choice. 
One copy of a signed form to be given to participant. 
Introduction 
Good day ......................... , my name is Mandisa Singata. I work for the 
Effective Care Research Unit. I am inviting you to participate in a research 
study to find out more about the advantages and disadvantages of different 
methods of contraception. I understand that you are requesting family 
planning method to prevent pregnancy. 
This study is part of Mandisa Singata's research for a PhD degree at the 
University of Cape Town. Title: U A randomised control trial studying the 
effects of the copper intrauterine device and injectable Progestogen 
contraceptive on depression and sexual functioning of women in the Eastern 
Cape". 
I would like to share some information with you and invite you to participate 
in this research study. Before you decide to participate you can talk to 
anyone you feel comfortable with about the research, including your family 
if you wish to do so. There may be some words in this form that you do not 
understand. Please ask me to stop as we go through the information and I 
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will take time to explain. If you have any questions later, you can ask me or 
any other member in the research team. 
Background 
Contraceptive non-use and method discontinuation are common causes of 
unintended pregnancy. The most common reason for method 
discontinuation is unacceptable side effects. This study will examine the 
potential association between two highly effective forms of contraception, 
the copper intrauterine device (IUD) and injectable Progestogen, and mood 
disorders. The study will specifically investigate the impact that initiation of 
an IUD or injectable Progestogen has on depressive symptoms and sexual 
functioning. Both depression and sexual dysfunction are given as side effects 
of contraceptive use; however, limited data exists to substantiate this claim. 
Purpose: 
The overall purpose IS to ascertain the impact, if any, of the IUD and 
injectable Progestogen contraceptives on depression and sexual functioning, 
amongst reproductive age women. The study will also compare the side 
effects of two methods of family planning: the 3 monthly depot injection 
(depot Provera), and the copper T380A intrauterine device (IUD). The results 
of this study will guide the choice, as we will have sound data on side effects 




The 'depot' injection is a hormone injection, which lasts for 3 months. The 
IUD is a small plastic and copper device, which is placed in the uterus during 
a gynaecological examination. It has two thin nylon threads attached, which 
are used to pull it out when the woman wishes to stop using this method. 
Both the methods (the' depot' injection and the IUD) are considered safe and 
effective methods of family planning and are recommended by the World 
Health Organization. All contraceptive methods have advantages and 
disadvantages. For both these methods, serious complications are very rare, 
and are less than the complications of unintended pregnancy. These methods 
do not protect against sexually transmitted diseases. To be protected against 
sexually transmitted diseases you need to use condoms as well. 
If you agree to participate in this study, I will provide contraceptive method 
for you either by means of the 'depot' injection, or by means of the IUD. The 
choice will be made by opening an envelope to find out which group you 
belong to. In addition, for the purpose of 
This study, I will ask you to complete a brief questionnaire at the start, and to 
complete the questionnaire by phone after 1 month and at 3 months. If 
adequate resources are available, we may contact you again after 6, and/ or 
12 months. You will be free to contact our research staff at any time should 
you have any worries or questions. 
Benefits of participating in this study: 
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All women in the trial will receive a safe and effective method of 
contraceptive, and will be offered careful follow-up and advice from the 
research staff should they have any worries or questions. If there is any 
health problem identified during the study, I will refer you for the necessary 
care. The main benefit will be the knowledge that you will be helping to 
provide more knowledge about these methods of contraceptive, which will 
help to provide the best possible information for women in the future. I will 
also provide you with the results of the research, and assist you to choose a 
contraceptive method after completing the study. 
Will you be paid to take part in this study and are there any costs involved? 
No you will not be paid. There are no costs expected from you as a 
participant, if you do take part. 
Risks & possible discomforts: 
Both contraceptive methods have risks and discomforts, but these are related 
to your need for family planning, not to the research. The Depot Provera 
need to have repeat injection every 3 months and might experience the 
following, menstruation may be irregular or stop, and there may be some 
nausea and weight gain. Disadvantages of IUD Putting in the 'IUD' may be 
painful- there may be increased menstrual flow and menstrual pain, rare 
complications such as infection or the 'IUD' penetrating the wall of the 
uterus (These complications are less than the complications of unintended 
pregnancy) 
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The strings may be felt in the vagina. If you prefer not to have the strings 
able to be felt they may be shortened, but this has disadvantages: not being 
able to check easily that the IUD is still present, and more difficult to remove 
it. 
It is not known whether one method is overa]] better or safer than the other 
is. The World Health Organization recommends both methods for 
widespread use. 
Confidentiality: 
Any information you provide during the study will be kept confidential. 
Your name will not appear on any report of the study, and only staff 
participating in the study will have access to the information you provide. 
Right to Refuse or Withdraw: 
You are free to choose whether you wish to participate. You are also free to 
withdraw from the study at any time should you wish to do so for any 
reason. If for any reason you are not eligible for the study, or decide not to 
participate, you will still receive normal care. 
Duration 
The interview that you will take part in will last approximately 30 minutes. 
During the telephonic interviews that are to be done at 1month and 3 
months, you are requested not to inform the interviewer which family 
planning method you are on. The study, on the other hand, will last until we 
complete the number required. 
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Ethical clearance 
This proposal has been reviewed and approved by the Faculty of Health 
Sciences Human Research Ethics Committee (FHS HREC) of the University 
of Cape Town, as well as the East London Complex Ethics committee. The 
purpose of these committees is to ensure that research participants are 
protected. If you wish to find out more about the FHS HREC, contact Prof 
Blockman at 021 4066492 (University Of Cape Town).Dr Alexander at 043 708 
2100 is the chair person for the ELHC ethics. 
We hope you will participate and thank you if you do. 
Whom to Contact: 
If you have any questions you may ask now or later during the study. You 
may contact ECRU Research team anytime at 073 7777753 or 043 709 
2482(Frere Hospital) or 0737778606 or 0437082302 (Cecilia Makiwane) 
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PART II: Certificate of Consent 
I have read the foregoing information, or it has been read to me. I have had 
the opportunity to ask questions about it and any questions that I have asked 
have been answered to my satisfaction. I consent voluntarily to participate 
as a participant in this survey and understand that I have the right to 
withdraw from the research at any time without in any way affecting my or 
my infant's future health care. 
Print Name of Participant _______ _ 
Signature of Participant ________ _ 
Date _______________ _ 
Day /month/year 
Print Name of Researcher -------------
Signature of Researcher ____________ _ 
Date ____________ __ 
Day / month/ year 
If participant, cannot read or write the form to be completed by either the 
researcher or research assistant. A literate witness must sign (if possible, this 
person should be selected by the participant and should have no connection 
to the research team). 
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I have witnessed the accurate reading of the consent form to the potential 
participant, and the individual has had the opportunity to ask questions. I 
confirm that the individual has given consent freely. 
Print name of witness. _________ AND 
Thumb print of participant 
Date ________ __ 
Day /month/year 
Signature of witness _________ _ 
Date ___________ __ 
Day /month/year 
I have accurately read or witnessed the accurate reading of the consent form 
to the potential participant, and the individual has had the opportunity to 
ask questions. I confirm that the individual has given consent freely. 
Print Name of Researcher ------------
Signature of Researcher __________ _ 
Date ___________ __ 
Day / month/ year 
An original copy of this Informed Consent Form has been provided to 
participant. 
An original copy of this Informed Consent Form will be filed in a secure 
place in the research unit __ (Initialled by the researcher) 
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Appendix B: (Xhosa) Infonnation and consent form. 
UNIVERSITY OF CAPE TOWN 
School of Health & Rehabilitation Sciences 
Faculty of Health Sciences 
Igama lomphandi 
Igama lombutho 
: Mandisa Singata 
: Idyunivesithi YaseKapa 
Igama lomxhasi ngezimali :Effective Care Research Unit, Eastern Cape 
Department of Health. 
Igama lesiphakamiso : "A randomised control trial studying effects of 
Intrauterine-device and Injectable Progestogen contraceptive on depression 
and sexual functioning of child-bearing women in the Eastern Cape" 
Umhla: July 2012 
Inombolo yophunyezo lwentsulugeko: FHS HREC: ref number 548/2012 
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Icandelo 1 Uxwebhu lolwazi 
Kufanele ifundwe ngumntu wonke onokuthatha inxaxheba eyifunda 
ngolwimi afunangalo.Elinye iphepha mvume izakuba lelakho elinye lishike 
kuthi, 
Molo. Igama lam ngu Mandisa Singata. ndisebenzela isebelezempilo apha 
kwimpuma koloniSiyakumema ukuba uthathe inxaxheba kuphando 
esilenzayo lokujonga ukuba zeziphi na izinto ezixhamlekayo 
anezingathandekiyo kwintIobontlobo zendlela zokucwangcisaSiyaqonda 
ukuba unqwenela ukucwangcisa ukhusele umitho. 
Intsusa 
Ukungasebenzisi ucwangciso kunye nokungaqhubekeki ned lela 
yocwangciso ngo nobangela abaxhaphakileyo bomitho obungakhange 
bucwangciswe.Esona sizathu sixhaphakileyo sokungaqhubeki nedlela 
yocwangciso zizinto ezithi zenzeke zingathandeki.Oluphando 
luzakuphonononga ukuba ikhona na phakathi kwezintIobo zimbini zo 
cwangciso iDepe kunye ne( IUD) enza kupekho ukunxunguphala 
ngokwasemoyeni. Oluphando luzakugxininisa ekujongeni ukuba iIUD 
Okanye isitofu se Depo sinenalo na igalelo kwimpawo zokubanomoya 
ophantsi(Depression) kunye nokungasebenzi kakuhle kwemizwa ngokwase 
ncantsini. Zombini iDepression kunye ned lela umzimba osebenza ngayo 
ngokwacecantsini zichazwa ngokuba ngezinye nezinto ezinokuthi zenziwe 
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yi Depo nangona kunjalo ingxelo izixhala lonto zimbalwa azikwazi 
ukuxhasa ncakasana. 
Injongo zoluphando 
Oluphando lunenjogo zokuqonda ukuba I IUD ne Depo ingaba zinegalelo 
naokanye azinalo kwi(Depression kunye nedlela obusebenda ngayo uburne 
bukasisi .sifuna ukuvula arnathuba okuba abantu babe nalo ithuba 
lokufurnana intlobo ezangeziweyo zokucwangcisa ebezingafurnaneki 
kuqala.oluphando luzakunceda ukuba sazi izinto esinokuzizuza 
nezingathandekiyo xa siqathanisa ezintlobo zirnbini oIuqhelekileyo 
oIusetyenziswayo Iokucwangcisa inaIiti ye Depo kunye ne IUD (intrauterine 
device) yona ke ayikho kurnasebe ethu ernpilo.Iziphurno zoIuphando 
ziyakusinceda ukuba sikwazi ukucebisa abantu ababhinqileyo ngolona hlobo 
olunokumsebenzela unrntu lokuncwangcisa kwixesha elizayo. 
Indlela ekuqhutywa ngayo oluphando 
Inaliti yeDepo inechiza elihlala ernzirnbeni inyanga ezithathu . 
IUD yona yinto yeplastic anentwana yekopa eyenzela ukuthinntela 
umitho.Ifakwa apha phakathi esibelekweni ngexesha uhlolwa ngalo 
ngaphantsi.Inernisonto ebityileyo elapha kuyo ekusentyenziswa yona xa 
ikhutshwa xa sele ufuna ukuyeka ukucwangcisa nge IUD. 
Zornbini ke ezintlobo zokucwangciswa zaziwa zingenabungozi kwaye 
zikhusela umitho.Umbutho wezernpilo eIizweni lonke (WHO) 
uyakukhuthaza ukusentyenzisaw kwazo. 
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• Zemke intlobo ezisentyenziswayo zokucwangcisa zinezinto 
esizizuzayo kunye nezingathandekiyo 
• Kuzo zombini ezindindi akukhonto enokuxhalisa ngazo.lziphumo 
ezinokuthi zothose zinqabile kakhule kwaye zingaphantsi kwengxaki 
enokuthi yenziwe lurnitho obelingalinelekanga. 
• Zombine ezintlobo azikukhuseleli ekosulelekeni kwizifo 
zocantsi.Kubalulekile ukuba uzikhusele ngokusebenzisa I "condom". 
Inaliti ye Oepo 
Izinto ezixhamlekayo kuyo 
• Kulula ukuyiniezela uncutswa ngenaliti 
Izinto onongazithandi 
• Kufuneka uzokuhlaba inali qho kwinyanga ezintathu 
• Kungenzeka uyeke ukuya exesheni okanye ungayi ngohlobo obukhele 
ngalo 
• Kungenzeka ubenisicefesefe ufune ukugabha 
• Ubunzima bomzimba wakho bungongezeleka 
• Kundenzeka ubenamaxhesha okuziva unxunguphele 
• Kunqabile ke kodwa ukuba ungo phuka lula amathambo okanye 
ufunyanwe 
sistroke. (Qaphela ezingxaki zingaphantsi kwengxaki yokukhulelwa 
ungafuni) 
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• Emva kokuyeka ukucwangcisa kungathatha ixesha ukuba ukhuIeIwe 
xasele ufuna. 
IUD 
Izinto ezixhamlekayo kuyo 
• Akukho sizathu sokuba uquqe ubuya ihiala ithuba elide elinokufika 
kwiminyaka elishumi 
elinesibini(12 years) iphakathi kuwe 
• Ayinamachiza anokukhathaza umzimba wakho 
• Awuyeki ukuya exesheni 
• Umitha kwangoko emvakokuyikhupha 
Izinto onokuthi ungazithandi 
• Xa kufakwa iIUD kungabakho intlungu 
• Kungenzeka ukuba wophe kakhulu xa usexesheni 
• Inqabile into yokupa leplastiki yeIUD inga kuhIaba esibelekweni (nangona 
kunjalo ayinaku qathaniswa nobunzima onoba kubo xa uthe wamitha 
ungafuni) 
• Imisonto Ie yeIUD ungakwazi ukuyiva apha kuwe ngaphakathi kunosisi 
wakho xa ufake isandla. Kodwa ukuba ufuna ingavakali ingasikwa 
ibemifutshane kodwa ke kungangabilula ukuba uzihlole uve ukuba isekhona 
na I IUD.Lonto ingenza kubenzima ukuyikhupha iIUD. 
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Ukuba uyavuma ukuthatha inxaxheba koluphando,Wokufumana nokuba 
loluphi uhlobo kula sesiwacacisile ngentla.5obabini sokwazi ukuba ungena 
koluphi uhlobo ngokuthi sivule imvulophu eyakuthi isixelele ukuba 
sikunike oluphi uhlibo. 
Njengokuqhelekileyo uzakufumana ingcaciso unikwe nethuba lokuba 
ungahlolwa kujongwe intsholongwane yengculazi xa ufuna. Yinto ke Ie 
eyenziwa kumntu wonke nokuba akazokuthatha nxaxheba 
koluphando.Njengenxalenye yoluphando sicela ukugcina ngokufihlakeleyo 
ingxelo zegazi lakho lokuhlolelwa ingculazi. 
Ngaphezulu sisela ukuba usiphendulele imibuzo thile ngoku xa uqala 
ukungena koluphando naxa usiza okokungqibela socela uphinde 
usiphendulele lemibuzo. 
Sothi ke emva kwenyanga yokuqala nakweyesithathu sikutsalele umnxeba 
s kubuze imibuzo ethile.Ukuba sithe sakwazi ukuphumelela sicela ukuba 
sikutsalele nakwixesha lenyanga ezintandathu,ezisithoba kunye naye tshumi 
elinambini. 
Uvumelekile nangalo naliphina ixesha ukuba usibuze imibuzo ukuba kukho 
into ekhukhathazayo. 
Okuyinzuzo kuwe 
Wonke usisi okoluphando wofumana unyango olukhuselekileyo lohlobe 
lokucangcisa.5iyakuku landelela ngokunonophekileyo sikuhlola.Maxa onke 
ukuba unemibuzo wofumana ingcebiso kwiqela elisebenzela 
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oluphando.Ukuba kunokwenzeka kubekho ingxaki ngokwasempilweni yakh 
siyakukuthumela kwinawo efanelekileyo yokukunyanga.Eyona nzuzo 
iyakuba lulwazi oyakuthi isityhilele lona ngezindidi zimbine 
zoncwangciso,olwakuthi luncede xa sicebisa abantu ababhinqileyo kwixesha 
elizayo ngocwangcoso ntsapho. 
Ukuba uyafuna siyakukunika iziphumo zoluphando ekupheleni 
kwesisifundo. 
Ingaba kukhona na intlawulo oyakuthi uyifumane ngokuthatha inxaxheba 
nencitho elindelekileyo. 
Akukho ntlawulo oyakuyifumana .. Akukho ncitho ilindelekileyo kuwe 
ukuba uthathe inxaxheba. 
Okwenzeka kube kungeyonjongo 
Zombini ezintlobo zinezinto onongazithandi,kodwa ke zizinto ezenziwa 
kukuba ufuna ukucwangcisa hayi ngokuba uthatha inxaxheba 
koluphando.Asiyazi ukuba ngeyiphi kwezi ntlobo sikunikazona enzono 
ukwadlula enye nekwakhuseleke kakhulu kunenye.Undlunkulu kazwelonke 
wesebe lezempilo (WHO) ukhuthaza ukuba zombini ezintlobo 
zisentyenziswe ukukhusela ukukhulelwa.Ngokudibanisele nokuthatha 
kwakho inxaxheba inye qha into enokuthi ikudube kukuphendula imibuzo 
yethu emalungelana nesisifundo. 
Okuyimfihlelo 
199 
Yonke inkcazelo oyinikileyo kwesi sifundo iya kugcinwa iyimfihlelo.Igama 
lakho aliyikuvela kwincadana zesi sifundo yaye ngabasebenzi 
ababandakanyekayo kwesisifundo kuphela abakubanegunya kwinkcazelo 
oyinikileyo. Igama lakho alizokubakho nakumagazi esiwathathileyo. 
Unelungelo lokungavumi okanye uyeke sele uqalile 
Akunyanzelekanga ukuba uthathe inxaxheba koluphando uvemelekile 
kananjalo ukuba uyeke nanagaliphi na ixesha nokuba sithini na isizathu 
sakho.Ukuba kuyenzeka ukuba akuku lungelanga ukungena koluphando 
lonto ayithi akuzokufumana unyango olufunayo kweliziko. 
Siyathemba uyakuyithatha inxanxeba ,siyabulela ngokwenje njalo 
Intloso yoluphando iye yapicotwa kwaye yafunyanwa ukuba kungile iqhube 
oluphando licandelo Ie (Faculty of Health Sciences Human Research Ethics 
Committee (FHS HREC) ye Ndzunivesiti yase Kapa.Kananjalo ne komiti ye 
East London hospital Complex Ethics committee(ELH CE) .Injongo 
zezikomiti kukuqinioseka ukuba abathathi nxanxheba koluphando 
bakhuselekile.Ukuba unqwenela ukwazi banzi unga tsalela umnxena 
usihlalo wekomiti(FHS HREC) Prof Blockman 0214066492.Xa ufuna Ie 
yalapha Emonti kwi (ELHCE) tsalela usihlalo wayo Dr Alexender 043 708 
2100 
Ngubani onokuthetha naye xa unemibuzo nokuba usekhaya 
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Ukuba unemibuzo ofuna iphendulwe ngexesha siqhuba oluphano 
ungatsalela umnxeba Umphandi owenza esisifundo. 
Abangikazi abasebenza kwa ECRU ngalo lonke ixesha ungabafumana 
kwezinamba 073 7777753 okanye 043 709 2482 (Frere hospital) kunye no 073 
7778606 okanye 043 7082302 (Cecilia Makiwane) 
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Icandelo II:IPHEPHA-MVUME LOKUTHATHA INXAXHEBA 
MNA ............................................................................. Ndifundile 
iphepha lenkcazelo malunga nesi sifundo kwaye ndicacelwe 
kwendizakwenza ukuba ndithathe inxaxheba . Imibuzo yam iphenduliwe 
kwaye ndiyayazi ukuba ndingayeka nanini na ndifuna ndinganiki sizathu. 
Oko akusayi kuchaphazela inkathalo endifaneleyo. 
Ndiyavuma ukuthatha inxaxheba kwesi sifundo. 
Tyikitya .............................. . Umhla ....................... . 
Igama lengqina ........................... . Umhla ....................... . 
Tyikitya(ingqina) ............. , ............ .. 
Umhla ......................... . 
Ndingathanda ukufumano iziphumo zoluphando/Nokuba anindazisanga 
iziphumo zoluphando (Yenza isangqa koyikhethayo) 
Oqhuba uphando(umongikazi / ugqirha) .................................... Umhla 
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